The potential for cost savings by extensively using generics for chronic conditions in South Africa. by Nicolosi, Elizabeth.
The Potential for 
Cost Savings by 
extensively using Generics 
for Chronic Conditions 




Submitted in partial fulfillment of the 
requirements for the degree of 
Masters in Business Administration 
In the 
Faculty of Management Studies 
University of KwaZulu-Natal 
Durban, South Africa 
2006 
Supervisor: Ms G. Manion 
Co-supervisor: Mr A. Gray 
DECLARATION 
The analyses in this thesis were conducted under the direct supervision of Ms Gill 
Manion and Mr Andy Gray at the University of KwaZulu-Natal, Durban, during 
2006. No work represented in this dissertation has been submitted to any other 
tertiary institution, either in part or full. The opinions and views expressed in this 
dissertation are those of the author, and do not necessarily reflect those of the 




The author wishes to express her sincere gratitude to the following individuals for 
their assistance in the preparation of this dissertation: 
Ms G. Manion, supervisor, Department of Sports Administration, University of 
KwaZulu-Natal, for her guidance, encouragement and constructive criticism. 
Mr A. Gray, co-supervisor, Department of Therapeutics and Medicines 
Management, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, 
for his expert guidance in the preparation of the statistical data of results and for 
his enthusiasm. 
Prof. J. Botha, Head of Department of Therapeutics and Medicines Management, 
Nelson R Mandela School of Medicine, University of KwaZulu-Natal, for her helpful 
advice and unfaltering encouragement. 
111 
DEDICATION 
I dedicate this work to my family, who have always encouraged me to better 
myself. I thank my husband Alessandro and my sons, Gianluigi and Nicola, for 
their support, encouragement and understanding. I would also like to thank my 
mother, Evelyn Thorn, for her belief in me, and the conviction that success is 




Economic factors are a major constraint to quality health care in Africa. One of the 
aims of the Department of Health in South Africa is to increase availability and 
affordability of medicine. One way of reducing the cost of drugs is by introducing 
legislation to control the price of drugs and by the promotion of generics 
(interchangeable multisource medicines which are cheaper copies of the original 
brand name drug). Protocols for the Prescribed Minimum Benefits (PMBs) for the 
27 conditions on the Chronic Disease List as published in the Government Gazette 
in 2003, were legally binding from 1 January 2004 and these conditions must be 
covered by all medical schemes. Medication prescribed for these conditions may 
have one or more generic substitutes and Government has allowed certain 
measures to be introduced by the medical schemes in order to contain costs. This 
study investigates the potential savings if generics are extensively used for these 
chronic conditions. 
A census was conducted on the 25 chronic diseases for which algorithms are 
available. The empirical quantitative data collected was calculated to quantify 
potential costs savings in respect of each algorithm. 
The major findings show that there are large cost differentials between originator 
drugs and their generic equivalents (97% in the case of prednisone) and smaller 
cost differentials between generics themselves (54.6% in the case of formoterol). 
This study also shows that there is a correlation between the number of generic 
equivalents an originator drug has and the percentage cost differential. A total of 
67.5% of all cost differentials between originator and generics are greater than the 
Department of Health's proposed 40% benchmark pricing. The results support the 
recommendations that government needs to implement various measures to 
encourage increased use of generics in this country and to look at realistic 
benchmark price controls. 
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CHAPTER 1 : INTRODUCTION 
1.1 Introduction 
Medicines make up an important part of the costs of any health system. Medicines 
account for about 10% of recurrent costs in the South African public sector, 
second only to personnel costs (Council for Medical Schemes, 2005). In the South 
African private sector, the higher percentage of costs attributable to medicines -
variably estimated at 30-40% - has in the past attracted the attention of regulators 
and legislators. Together with private hospitals and medical specialists, medicines 
have in the past been responsible for more than 75% of all medical scheme 
payments (Council for Medical Schemes, 2005). 
In 2005, numbers of principal members and beneficiaries belonging to a medical 
scheme increased by 3.5% and 2.6% respectively from 2004. A total of R45.8 
billion was paid out in claims by registered medical schemes in South Africa in 
2005 (Council for Medical Schemes, 2005) This included hospital services, visits 
to medical / dental specialists, general practitioners, medicines dispensed and 
visits to supplementary and allied health professionals. Although there was a 
significant decline in expenditure (down 8.8% from 2004) in the value of medicines 
dispensed by pharmacists and providers other than hospitals, R7.2 billion (15.7% 
of the total benefits) were paid out by medical schemes. However, benefits paid to 
medical specialists, general practitioners and dental specialists increased by an 
average of 17% (Council for Medical Schemes, 2005), Medical schemes 
encourage their members to manage their own health care benefits more closely, 
not only for the members to achieve optimal use but for the medical schemes to 
remain sustainable. One of the ways members may achieve this is by substituting 
generics (interchangeable multisource medicines which are cheaper copies of the 
original brand name drug) for brand name drugs, where possible. 
1.2 Background 
Medicines are not regarded as ordinary articles of trade, but are instead subject to 
a variety of regulatory systems and interventions by government. This section 
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covers the basic controls over medicines in the South African setting and also 
deals with the policy developments in relation to the use of generic medicines. 
The promotion of generics by the South African Government is seen as a welcome 
and vital step to reducing health care costs in South Africa. The promotion of 
generics has long been supported by the World Health Organisation (WHO) and 
intervention by the South African Government has seen an overhaul of the system 
in recent times (World Health Organisation, 2004). 
The Medicines Control Council (MCC) of South Africa was established in 1965 as 
a statutory body in terms of the Medicines and Related Substances Control Act 
(1965) (Medicines and Related Substances Act, 1965). Through its main function 
of overseeing the regulation of medicines, more than 20 000 medicines have been 
approved, applications for more than 11 800 complementary medicines have been 
submitted for evaluation and 280 clinical trials have been approved annually 
(Medicines Control Council, 2006). The prescribing and dispensing of medicines 
is controlled through the determination of schedules for various medicines and 
substances. The MCC operates through non-governmental external experts who 
are members of the Council's Committee structures. Dossiers, submitted by the 
pharmaceutical industry for purposes of registration, are evaluated by the experts 
who are mainly from academic institutions e.g. medical and pharmacy schools. 
The Department of Health aims to promote the health of all people in South Africa 
and one of Government's aims is to increase availability of medicine. 
Government's broad policy in this regard was spelled out in the 1996 National 
Drug Policy (NDP) (Department of Health, 1996). Although Cabinet approved at 
the time, the NDP was also given additional formal status by being included as an 
appendix to the White Paper on the Transformation of the Health System in South 
Africa, issued in 1997. 
The NDP outlines three sets of objectives: 
• Health objectives 
• Economic objectives and 
• National development objectives. 
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There are specific broad aims for each: 
• Health objectives 
o to ensure the availability and accessibility of essential drugs to all 
citizens 
o to ensure the safety, efficacy and quality of drugs 
o to ensure good dispensing and prescribing practices 
o to promote the rational use of drugs by prescribers, dispensers and 
patients through provision of the necessary training, education and 
information 
o to promote the concept of individual responsibility for health, 
preventive care and informed decision making. 
• Economic objectives 
o to lower the cost of drugs in both the private and public sectors 
o to promote the cost-effective and rational use of drugs 
o to establish a complementary partnership between Government 
bodies and private providers in the pharmaceutical sector 
o to optimize the use of scarce resources through cooperation with 
international and regional agencies 
• National development objectives 
o to improve the knowledge, efficiency and management skills of 
pharmaceutical personnel 
o to re-orientate medical, paramedical and pharmaceutical education 
towards the principles underlying the National Drug Policy 
o to support the development of the local pharmaceutical industry and 
the local production of essential drugs 
o to promote the acquisition, documentation and sharing of knowledge 
and experience through the establishment of advisory groups in 
rational drug use, pharmacoeconomics and other areas of the 
pharmaceutical sector. 
(Department of Health, 1996). 
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A number of these objectives deal with access to affordable medicines, 
strengthening medicines selection process, greater use of economic techniques 
and data and reorientation of professional attitudes. They also include potentially 
conflicting provisions, such as the aim to not only reduce medicine prices but also 
to stimulate the local industry. In a sense, they also represent the realization that 
economic factors are a major constraint to access of quality health in South Africa, 
as in the rest of Africa. It has been noted, for example, that 65% of drug 
expenditure in sub-Saharan Africa is 'out of pocket' expenses (Gray and 
Matsebula, 2000). 'Out of pocket' expenses refer to the actual expenses made by 
patients themselves as opposed to the health system. One way of reducing the 
cost of drugs is by introducing legislation to control the price of drugs. When an 
Essential Drug List (EDL) is compiled, cost is a factor which is taken into 
consideration when determining the inclusion or exclusion of a drug (Gray and 
Matsebula, 2000). 
Under a less regulated policy environment before 1994, the minimum benefits 
provided by medical schemes in South Africa were gradually whittled away. This 
was largely reversed with the passage of the Medical Schemes Act (1998), which 
offered greater protection for consumers (Department of Health, 1998B). The Act 
provided for the definition of Prescribed Minimum Benefits (PMB), which stipulate 
a package of services or care a medical scheme must provide for in its benefit 
design. A very important result of the Act was that medical schemes were not able 
to discriminate on the basis of age, medical history and health status. A patient 
could not be held to a 'waiting period' when joining a medical scheme, if s/he had 
been a member of a medical scheme for the previous two years. Contributions 
could only be determined on the basis of income and number of dependents. This 
has resulted in more affordable options available to members of medical schemes. 
Following the same principle, the PMB package was extended with the 
introduction of a Chronic Disease List (CDL). Not only were the conditions listed, 
but Professor Jan van der Merwe (from the University of Pretoria and a member of 
the Council for Medical Schemes) was asked by the Department of Health to draft 
protocols for the 25 original conditions on this list (SASP, 2004). The Council for 
Medical Schemes is a statutory body, established by the Act to provide supervision 
over medical schemes. The final algorithms for the 25 conditions on the CDL were 
4 
published in the Government Gazette at the beginning of August 2003 and were 
legally binding from 1 January 2004. Since that time Government has increased 
the number of chronic conditions to 27, including HIV/Aids and Bipolar Mood 
Disorder. However no algorithms have been drawn up for these latest two 
conditions. In terms of HIV/AIDS, the injunction is that a medical scheme should 
provide at least those services and treatments that are provided by the State 
(Department of Health, 1998B). 
Under the Medical Schemes Act (1998) the current 27 chronic conditions must be 
covered by medical schemes. Medical Schemes have to provide benefits for the 
treatment and medicines and pay for the full management of the 27 conditions with 
no co-payments. Medication prescribed for the 27 chronic conditions may have a 
generic substitute and in many conditions more than one substitute may be 
available. By making these benefits mandatory, the government hopes to curtail 
attempts by schemes to rate members on the financial risk they pose to the 
scheme because of the state of their health. Medical Schemes had previously 
made chronic benefits available only on options with higher contribution levels. In 
this way, people with chronic conditions were effectively being risk-rated and 
forced to pay higher amounts for their cover. 
In order to contain the costs incurred by providing PMBs for the chronic conditions 
and to ensure that schemes can financially cover their members who need this 
benefit, the Regulations to the Medical Schemes Act (1998) have allowed certain 
measures to be introduced by the medical schemes. One of these measures is 
that the medical scheme may draw up a list of safe and effective medicines 
prescribed to treat certain conditions, known as a formulary. The scheme may 
state in its rules that it will only cover the member if a doctor prescribes a medicine 
on their formulary. Many of these medicines are generics and if a brand name 
medicine is prescribed and dispensed, the scheme has the right to refuse to either 
cover it completely or will only pay the equivalent of the generic up to a fixed 
monthly medicine limit (Department of Health, 1998B). 
The Government is also looking at creating a medical scheme for low income 
earners, who at present are excluded from private medical aids due to the high 
5 
premiums. A Government Employees Medical Scheme (GEMS) was introduced 
in January 2006 for public service employees. There are also calls for a National 
Health Insurance System, or at least a Social Health Insurance option, which will 
include all employed South Africans. The next phase of policy development will 
see schemes required to develop a minimum package of services that will be 
made available to all members. The Minister intends to table an Amendment Bill to 
this effect in early 2007 (National Health Act, 2004). 
1.3 Motivation for the Research 
As everyone is affected by the high cost of medicines, this is an area of wide 
interest to researchers. The ways in which the government has intervened in the 
health sector are the subject of considerable media and public interest. During the 
past few years there has been a lot of publicity with regard to medical schemes, 
and in particular how they can remain viable while providing cover for the wider 
population, whilst complying with the requirements of the Medical Schemes Act 
(1998). One way they can do this is by reducing the costs of medicines claimed. 
Whilst the current formularies set out by medical schemes encourage the use of 
generics, their use is not universal, nor do they have the weight of law, as do the 
PMB treatment algorithms. It is envisioned this study will determine whether there 
is the potential for cost saving if the use of such products is maximized and if so to 
what extent. This could provide the motivation for more explicit legal and policy 
interventions in this area. 
1.4 Value of the Project 
The potential for cost savings, in the South African context, that could be achieved 
in relation to the Council for Medical Schemes' 27 chronic conditions has not been 
studied. Although it is understood that a cost differential between originator and 
generic drugs exists, it is hoped that this study will quantify the scale of cost 
differentials with specific reference to those drugs used in chronic diseases listed 
by the Council for Medical Schemes. Not only is there a benefit in prescribing a 
generic over a brand name but, with an increase in knowledge of the different 
generics available, there will be a saving depending on which generic is 
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prescribed. Recommendations will be made to implement these findings for the 
benefit of the patient and medical schemes. 
1.5 Problem Statement 
In general, the Formularies set by medical schemes encourage the use of generics 
and should help make coverage of the Prescribed Minimum Benefit chronic 
disease list more affordable. This is, however, not true in every case. There is 
also minimal co-ordination between this private sector system and the Essential 
Drug List (EDL) and Standard Treatment Guidelines (STG) applied in the public 
sector. 
There are sufficient generic equivalents available to meet the prescriptions of the 
treatment algorithms for chronic medical conditions, included as Prescribed 
Minimum Benefits for medical schemes in South Africa and if use of these is 
maximised, cost savings will accrue. 
1.6 Objectives 
The objective of this study is to determine the extent to which a new policy 
approach, in terms of generic medicines use in the private sector, can be applied. 
Specifically, this study will focus on the Chronic Disease List that has been added 
to the Prescribed Minimum Benefits prescribed in terms of the Medical Schemes 
Act (1998). In each case: 
• the number of generics available for the treatment of each chronic condition 
will be established; 
• the single exit price (SEP) and the Defined Daily Dose (DDD) of each drug 
will be used to compare monthly treatment costs; 
• the existing cost differentials, on an acquisition cost basis, will be 
determined, between generic medicines themselves as well as between the 
generic and the brand name drug; 
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• the prescribed algorithms will be compared with the equivalent Standard 
Treatment Guidelines/Essential Drugs List, where possible. 
The research conducted and the results obtained will show whether, within a 
number of different generics and brand name drug for a single chronic condition 
there is the potential for further cost savings. This information will be useful to 
medical schemes as it will enable them to re-evaluate their formularies. Patients 
aware of the drugs available on the formularies, will be in a stronger position to 
decide whether to substitute a prescribed brand name drug with a generic and, if 
information is available, which one. The algorithms prescribed by Government 
may be too broad and through the data gathered recommendations may be made 
to enhance the algorithms to make them more cost effective for all. 
As reliable prevalence data for all 27 Chronic diseases for the entire country, or 
even for the private sector in particular, are not available, no net potential cost 
savings can be computed. 
1.7 Limitations to the Project 
The South African pharmaceutical market is a dynamic one, and is subject to large 
numbers of changes every month. New medicines are registered and become 
available, whereas manufacturers may make decisions to withdraw certain 
products from the market, for largely commercial reasons (Global Health Watch, 
2005). 
The following potential limitations have been identified, and the action indicated 
has been taken to reduce, as far as possible, the impact of each limitation on the 
validity of the research results: 
• The actual cost to the patient is greater than the SEP, and includes a 
variety of dispensing fees, delivery fees and other professional charges. 
This is an area of considerable contention and has been the subject of 
several court actions (e.g. New Clicks and Others v. Minister of Health and 
Others, Cape High Court. 2005) during the past two years (Minister of 
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Health and Another v New Clicks South Africa (Pty) Ltd and Others, 2005). 
In order to keep to a consistent method, only the acquisition cost - the SEP 
- was used in this study. 
• Originator (branded) medicines and generic medicines are often presented 
in a variety of strengths, which may cost different amounts per unit of active 
ingredient. Different doses may also be used for the same indication. In 
order to be consistent about the doses and hence the quantities compared, 
it was decided to use a standardized, internationally-acceptable measure of 
utilization, the defined daily dose (DDD) (World Health Organisation, 2006). 
This dose may not represent a clinically-relevant dose, and may in fact be a 
dose that is never used, and that is not possible to obtain with existing 
formulations and strengths. However, by using the lowest cost within the 
available strengths for a particular medicine, consistency could be 
achieved. In addition, only adult formulations were considered, as these 
would constitute the vast majority of chronic disease patients covered by 
any one medical scheme. 
• The range of generic medicines available varies from month to month, and 
is not always easily accessible. In order to be consistent, the most widely 
consulted reference used by medical practitioners was relied upon to 
identify generic medicines. This is the Monthly Index of Medical Specialties 
(MIMS), which is published monthly. Price information was also obtained 
from a single source, the online Blue Book. Where a medicine class rather 
than a specific medicine was listed in the algorithm, the members of that 
class that are used in South Africa were identified from a single source, the 
South African Medicines Formulary (2005). 
• The public sector treatment guidelines vary to some degree between 
provinces and over time. In order to maintain consistency, only the relevant 
guidelines from the 2003 Primary Health Care and the 1998 Hospital level 
national guidelines were used (Department of Health, 1998A). 
• As mentioned above accurate prevalence data for each of the 27 chronic 
diseases are not easily obtainable. In addition, the management of each 
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disease may involve one or more of the listed drugs and at varying doses. 
Determining a cost per patient is thus difficult without knowing more about 
the spread of the severity of the diseases and prescribing patterns. These 
may also vary over time. A dynamic model taking into effect all of these 
factors is beyond the scope of this project. 
1.8 Structure of the Study 
Chapter One : Introduction 
The background and motivation for this study is discussed providing the history 
and regulatory framework. The aims and objectives of this study are included in 
this chapter. 
Chapter Two : Literature Review 
In this chapter a discussion of the theory of generic substitution is covered. 
Among the topics looked at are consumer perceptions, brand loyalty, and the 
benefits of generics. A review of current literature is presented and the importance 
of the cost savings potential is explained. An insight into how other people have 
approached their research is also provided. A look at the current situation in South 
Africa with regard to this topic is included. The basis is laid for the exploration of 
the relationship between what is reviewed and what the study determines. 
Chapter Three : Methodology 
The theory of the research methodology is discussed and identification of the data 
required is presented in this chapter. This chapter explains, step by step, the 
methods used to obtain this data. Various methods of data collection are possible, 
and these are discussed in some detail with an explanation of the decision taken 
with regard to the path this study followed in respect of data collection. 
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Chapter Four : Results and Discussion 
The analyses of data take the form of Excel spreadsheets, tables and graphs. A 
comparison of medicine acquisition costs is used to show the potential cost 
differentials between originator drugs and their generic equivalents. It is shown 
that certain patterns appear, highlighting a range of cost differentials between 
different generics within a particular class and condition. 
Chapter Five : Recommendations and Conclusions 
This chapter uses the results of the data analyses in Chapter Four to present 
conclusions and recommendations. In chronic conditions with generic equivalents 
available, there is potential for large cost differentials between the originator drugs 
and the generics. 
1.9 Conclusion 
This chapter has introduced the subject for this dissertation and provides the 
background, motivation, value and limitations. This study only looks at 25 of the 
27 (excluding HIV/Aids and Bipolar Mood Disorder) chronic conditions presently 
covered by medical schemes. The results of this study will enable various 
stakeholders, including the Council for Medical Schemes, to review each 
algorithm, note the cost differentials reported and if necessary adjust the algorithm. 
Prescribers will also have more knowledge of the cost implications for the patient 
of prescribing generics as opposed to brand name drugs. The next chapter 
discusses the related literature examined prior to embarking on this study. 
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CHAPTER 2 : LITERATURE REVIEW 
2.1 Introduction 
This chapter discusses the high cost of medicines and the various reasons. 
Different pricing policies are reviewed and discussed with analyses of research on 
existing examples. A look at other research studies into the potential savings of 
using generics is also discussed. 
Strategies that affect the life of brand-name drugs is noted and branding in the 
pharmaceutical industry is looked at, discussing whether this will change 
consumers or practitioners habits. 
2.2 Importance of controlling drug prices 
South Africa is one of the many countries faced with high and increasing health 
care spending. The high rate of HIV/Aids among the population including those on 
private medical schemes has placed an increasing burden upon private medical 
schemes and patients. The cost of medical schemes are prohibitively high and 
only about 7 million people in South Africa (approximately 16% of the population) 
belong to them. These 7 million people however, contribute to more than 50% of 
the total cost of healthcare in this country (Cullinan, 2003). High pharmaceutical 
costs are a major contributing factor to the increase in health care spending. R5.5 
billion is spent on medicines in the private sector in South Africa every year, 
compared to R2.5 billion in the government sector (Enslin, 2003) and drug costs 
are the single biggest cost driver. According to the South African Health Review 
2000, 27% of the money paid out by medical schemes in 1998 was for medicines 
while medicines accounted for 28.5% of payments made to private hospitals (Gray 
and Matsebula, 2000). There is a need to reduce the drug expenditure in the 
private sector as in 1998 per capita expenditure of drugs in the public sector was 
R59 compared to R641 to R800 in the private sector. Although much has changed 
in the last decade, these were the last figures from comparable surveys in both 
sectors, performed as a part of the National Health Accounts Project 1998 
(Muirhead and Thomas, 2000; Cornell etal., 2001). 
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Approximately 17.75% of the South African population have a disease on the 
Chronic Disease List (CDL) (Bester et al., 2005). Total chronic medicine 
expenditure, including the CDL diseases, makes up 44% of total medicine 
expenditure. Figure 2.1 shows that the 27 CDL diseases are responsible for 23% 
of total medicine expenditure (Bester et al., 2005). 
Non-CDL chronic 
2 1 % 
CDL Chronic 
23% 
Acute and other 
56% 
Figure 2.1 CDL expenditure as a percentage of total medicine expenditure, Q4 
2005 (Source: Mediscor Medicines Review 2005) 
The higher the prevalence of the disease, the greater the percentage towards the 
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Figure 2.2 Percentage prevalence vs. percentage total cost of each CDL disease 
(Source: Mediscor Medicines Review 2005) 
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It should be noted that these prevalence figures are only for beneficiaries of 
schemes administered by Mediscor. They can be extrapolated to the entire 
private sector with any degree of certainty. 
Taking into consideration distribution costs, retail mark-up and dispensing fees 
in South Africa, the producer's exit cost still accounts for the highest proportion 
of the actual drug costs, approximately 60%, while 40% is constituted by the 
distribution chain costs (Gray and Matsebuia, 2000). The retailer in the 
pharmaceutical industry is either a pharmacist in a retail pharmacy or private 
hospital or a dispensing doctor (Fig 2.3). 
Manufacturer • Wholesaler Retailer Patient 
Figure 2.3 Traditional distribution chain for medicines (Source: South African 
Health Review 2000. Drug Pricing) 
However, in a study comparing similar products in other markets, South Africa 
had 38 out of the 42 generic medicines studied with lower exit prices. In only 
one case was the South African generic more expensive (Bodhania, 2005). 
The aim of the National Drug Policy (1996) (Department of Health, 1996) is to 
promote the availability of safe and effective drugs at the lowest possible cost. 
South Africa looked at various policy options to reduce the price of drugs (Gray 
and Matsebuia, 2000): 
• Direct price control. This refers to the direct intervention of Government 
on fixing prices. This is not conducive to good trade practice as it is open 
to abuse. 
• Reference pricing. A national authority sets the lowest price for a drug 
by comparison with similar therapeutic drugs. Government and Medical 
Schemes will only agree to pay the reference price and the patient will 
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have to cover the shortfall if a branded drug is chosen. The price set 
may be decided on in different ways: 
o Making it equal to the cost of the lowest priced drug in the group. 
o By comparing prices of a 'basket' of drugs with same in other 
countries of similar economic standing as South Africa. 
o Averaging the price of the drugs available within that group and 
either setting the average price or stipulating a price lower than 
that. 
• Equity pricing. Under this option producers would subsidise the prices of 
drugs to developing countries by levying higher prices in non-developing 
countries. However, there is always the possibility that the subsidized 
prices come with pre-conditions. 
• Promotion of generic use. This option promotes competition which 
brings a reduction in prices. 
An Equity pricing policy, where developing countries are sold medicines at a 
'discount' while non-developing countries pay a premium, may not suit a 
developing country as it may be - or perceived to be - less reliable and hence 
less appropriate for basing a sustainable strategy. The main reason is that they 
may feel that it puts them in a very weak position regarding their negotiating 
capacity on other issues. In other words the 'discounted' medicines may come 
with 'conditions' (Rovira, 2003). However, developing countries who are battling 
with a large percentage of their population infected with HIV/Aids are receiving 
antiretrovirals at a lower price. Another problem with Equity pricing is that 
cheaper drugs may end up being re-routed and sold at a higher price to non-
developing countries for profit (T Hoen, 2001). 
Germany introduced reference pricing for prescription drugs in 1989, followed 
by the Netherlands in 1991, Denmark and Sweden in 1993, Spain in 2000, and 
Belgium and Italy in 2001. Norway, having adopted reference pricing in 1993, 
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dropped it in 2001 after the expected savings did not materialise (Kanavos and 
Reinhardt, 2003). In New Zealand, reference pricing was introduced in 1994. 
H2 antagonists were the first drugs to come under this policy and savings of $NZ 
27.6 million had been realised as of June 30, 1995 (Moore, 1995). However, 
reference pricing may not benefit all countries. In a highly competitive market, 
for example the United States, it may force the price of patented drugs down, 
reducing profits and limiting the introduction of new drugs (Danzon and 
Ketcham, 2003). 
South Africa is in the process of implementing a pricing policy, the results of 
which are expected to be implemented in January 2007 but are again a subject 
of a court action. It is expected that South Africa will follow a reference pricing 
option as it is one of the easiest to implement and monitor (Department of 
Health, 1996). The Government will set a 'reference price' based on comparing 
prices of an identical 'basket' of drugs from countries of a similar economic 
standing. Medical Schemes may then choose to reimburse the cost of 
medicines in various ways. They may require the patients to pay the full 
difference between the retail price and the stipulated reference price or they 
may only reimburse a percentage of the reference price to keep the volume of 
drugs used down. 
An effect of controlling drug prices is the decrease in expected profit for a drug 
company who has invested in the research and design (R&D) of the drug. In 
an article by Giaccotto (2005), it is stated the introduction of price controls may 
have a negative effect on the amount of investment a company commits to 
R&D. Giaccotto (2005) goes on to estimate that a decline in drug prices of 10% 
or 50% would cause a decrease in R&D investment of approximately 6% and 
29% respectively (Giaccotto et al., 2005). The lack of innovation (e.g. improved 
routes of administration or better dosages) by pharmaceutical companies will be 
detrimental to the patient in the long term. Another effect of price controls is a 
traditional demand and supply one. If the price of a drug is decreased, more 
people can now afford it and the demand increases. When the demand for a 
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particular item increases, the price of this item along with its quantity goes up as 
well. However, with price control, the quantity demanded still goes up, but the 
price is capped and therefore cannot rise above its restricted level. The price 
ceiling therefore generates a shortage for the particular good and patients are 
adversely affected (Gannon etal., 2006). 
The South African Government and private medical aids are very active in 
promoting the use of generics. It has been shown that generics can play an 
important role as an alternative to brand medicines in treating diseases and that 
more expensive medicines do not necessarily translate into better healthcare 
(Hassali et a/., 2004). Along with this important role is the saving that results 
from the use of generics. Generic forms are typically less expensive than 
brand-name drugs due to the fact that the large financial cost of research and 
development of brand name medicines is not applicable to the production of 
generics. 
However there is current debate over the actual cost of developing and 
introducing a brand name drug on to the market. According to the Tufts Centre 
for the Study of Drug Development it costs on average US$800 million to put a 
new brand-name drug on the shelf (DiMasi et al., 2003). The Tufts Centre is 
funded by the pharmaceutical industry and would obviously show what these 
pharmaceutical companies would like the public to believe i.e. that the industry 
is very competitive and, therefore, a high-risk one. The image they would also 
like to portray is one of an industry only just breaking even after research and 
development costs while still bringing innovative medicines to the public. 
Public Citizen, a consumer organization, conducted a detailed study of the 
figure above and determined that the US$800 million was inflated by about 75% 




half of this figure 
is made up of 
'opportunity costs 
of capital' - what 
the money could 
have earned if the 
money had been 
spent elsewhere 
instead of on 
research. 
$403 m The Tufts 
study says this is 
the actual out-
pocket R&D cost. 
But that is before 
tax. Companies in 
the US deduct 
34% of their R&D 
expenses under 
federal tax law. 
$240m This is the 
real cash outlay 
after tax breaks -







$71-118m This is 
the figure Public 
Citizen calculated 
as the rough R&D 
cost for new drugs 
brought to the 
market between 
1994 and 2000 
based on data 
from the drug 
industry. 
Figure 2.4 How much does it cost to develop a new medicine? 
(Source: Global Health Watch 2005) 
The difference in calculation between the Tufts Centre and the consumer 
organisation, Public Citizen, is shown in Fig. 2.4. There are different views on 
the actual cost of R&D, which from a manufacturers point of view is passed on 
to the consumer. It is believed that it would be extremely valuable if the actual 
costs of R&D could be clearly established. However, this is beyond the ambit of 
this study. 
According to an article by Welch (2005) medicine prices rose on average 7.1% 
above inflation in the USA in 2004. This was more than twice the general 
inflation rate in that country (Welch, 2005). Unfortunately, South Africa has also 
had higher than inflation rate increases in drugs resulting in prohibitively high 
costs prompting patients and medical schemes to look at ways of reducing this 
cost. Government and private medical schemes are urging their patients, 
doctors and pharmacists to use generics more often to cut costs. However, 
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according to Freudenheim (2002) costs of generics are increasing twice as 
much as brand-name drugs. This would appear to run counter to the expected 
pricing behaviour. When a patent expires on a brand-name drug the initial 
generic has 'exclusive rights' for a certain period, usually six months. This initial 
generic comes on the market at a higher than normal introductory cost. The 
price of the initial generic drops after the exclusive right period ceases and more 
generics come onto the market. Another reason for the sharp increase in 
generic prices is that the generic manufacturers are joining together, leaving 
fewer companies and therefore less competition. This can be 
counterproductive in that the lower prices translate into lower profits forcing 
smaller companies to withdraw from the market and prices start to increase 
again (Freudenheim, 2002). 
Prices of brand name drugs do not decrease when a generic is introduced into 
the market. If the generic is manufactured by the same company that made the 
brand name drug, there was no difference in the way the company viewed their 
pricing strategy. Many Canadian private medical schemes do not require nor 
promote generic substitution and, therefore, pharmaceutical companies do not 
feel the need to decrease their prices, in fact price increases sometimes occur 
to offset the decrease in volume sales (Lexchin, 2004). In Canada, since the 
Ontario Drug Benefit Formulary was introduced, the initial generic must be 
priced at no more than 70% of the brand name drug and subsequent generics 
must be 10% less than the initial one (Lexchin, 2004). 
2.3 Potential Savings 
In 1996 the potential savings by using generics in South Africa was studied by 
analyzing generic prescribing by doctors and generic substitution by 
pharmacists. The methodology used was to analyse prescriptions gathered 
from pharmacists and compare with what was actually dispensed. Only 13.9% 
of pharmacists substituted generics for brand-name drugs which saved the 
patient 1.4% of the original cost of the prescription. It was found that a further 
6.8% could have been saved by total generic substitution and 9.9% by total 
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generic prescribing (Karim et al., 1996) A similar study was conducted in 
America. A random sample of adults who had used at least one outpatient drug 
that had a generic was taken from a government survey conducted from 1997 
to 2000. The survey included medical and health data including insurance 
coverage and amount spent on each brand-name drug. The potential savings 
of replacing brand-name drugs with generics were then calculated. Although 
56% of the prescribed drugs had a generic substitute, patients used the generic 
form in only 61% of these cases. It was calculated that if generics had been 
used in all cases a savings of US$46 per person under 65 years would have 
resulted while in those over 65 the savings would have been US$78. Taken 
overall this would have given a national savings of US$5.9 billion in the younger 
group and US$2.9 billion in the older group. The reason for the difference in 
savings for the ages is that older patients tend to require more medication but 
constitute a smaller percentage of the population (Haas et al., 2001). 
In a recent study conducted in South Africa by Djolov (2003), the top 200 drugs 
by sales value (which represents 53% of prescription drugs) were taken and 
compared to their bioequivalent generic (if available). Prices obtained through 
the Monthly Index of Medical Specialities (MIMS) were used to calculate 
savings by comparing the price of the brand name drug to the cheapest 
available generic. It was shown that a total savings of 6.1% could be achieved 
by generic substitution. Interestingly, 4.14% savings was achieved in the top 
100 and only 1.96% in the next 100 drugs. If 1,96% is taken as the average for 
the remaining 47% of drugs, a total savings of R407 million could be achieved 
(Djolov, 2003). By looking at drug prescribing in the elderly using two groups, 
one with a private medical aid and the other with the government medical care 
programme there seems to be a higher potential for savings in the first group 
than in the second. This could be explained by the fact that the restrictions on 
the excess spending on brand name drugs which is already in place by the 
government medical programme may be working. There are large savings that 
could be realised by private medical schemes if the use of generics were 
encouraged more actively (Fischer and Avorn, 2004). 
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Competition among manufacturers can force prices of generic drugs to 
decrease more than the brand-name drug, resulting in a low ratio between the 
two prices. However, as can be seen in Table 2.1 the smallest ratio was only 
0.39 which still points at a large price gap between the generic and brand-name 
drug (Cook, 1998). 
Table 2.1 Price Comparison of generic and brand-name drugs, by number of 
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2.4 Consumer Behaviour and Decision Making 
Figure 2.5 shows that there are four types of consumer buying behaviour 
(Kotler, 2003:201). 













Figure 2.5 Consumer behaviour (Kotler, 2003: 201) 
Most medicines are prescribed by doctors and the 'buying decision' has 
effectively already been taken away from the consumer. The consumer cannot 
choose the type of medicine prescribed but can ask and decide whether to use 
a generic. The only difference between the originator and a generic is the price. 
As there is very low involvement in making the buying decision a consumer 
displays habitual buying behaviour. Consumers displaying this buying 
behaviour are usually passive recipients of advertisements which may only 
reinforce brand familiarity rather than brand conviction. Thus the consumer 
does not search extensively for information, evaluate characteristics and make 
a decision. The lack of television and print advertisements reflects this aspect 
of habitual buying behaviour. The two factors which can influence a consumer 
between the time of intention to purchase and the actual purchase i.e. attitude 
of others and unanticipated situational factors, does not normally apply to the 
purchase of essential goods such as medicines (Kotler, 2003: 207). 
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As generics are chemically identical to the originator drugs their 
pharmacological effects are exactly the same. However, there have been 
reports of generics not working (e.g. patients taking the generic of clozapine 
have reported a deterioration of their condition) (Mofsen and Baiter, 2001). This 
lends itself to the negative perception that patients often associate with 
generics. Lost sales driven by brand switching and negative word of mouth are 
estimated at US$15 - 20 billion annually (Manchanda et al., 2005). However, 
consumers today have greater access to more and detailed information on 
diseases which changes them from being passive consumers to taking a more 
active part in the decision-making process of their health care, even to question 
and override doctors decisions (Merino-Castello, 2003). Unfortunately, 
Formularies put forward by medical schemes may affect consumers and 
prescribers decision process by limiting the choice of medicines that medical 
schemes will fully cover for chronic diseases. 
In a study by Wosinska (2005: 323-332), on the effect of direct-to-consumer 
advertising, it was discovered that advertising had a more positive effect on 
compliance for patients taking the competitor drug and a negative effect (non-
compliance) in patients taking the advertised drug. She hypothesises that this 
could be due to the fact that the advertising involves not only promoting the 
benefits of the drug but also the possible side effects (Wosinska, 2005). There 
is another danger to pharmaceutical advertising in that a consumer may identify 
with the symptoms portrayed in the advert and will visit a doctor requesting that 
particular drug. There is a 70% chance that the doctor will comply with the 
request. The reason for this is that doctors are exposed to drug advertising by 
pharmaceutical companies through medical journals, drug representatives, drug 
companies and pharmacists (Veracity, 2005). 
In a short study conducted by Govender et al. (1999) it was shown consumers 
were more wary about taking or substituting a generic as the perceived 
seriousness of their disorder increased. In many patients cost savings will not 
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out weigh therapeutic benefits and many will still demand brand name drugs if 
this is in doubt (Govender etal., 1999). 
2.5 Prescriber behaviour 
After the generic drug scandal in the USA in 1989, where Food and Drug 
Agency (FDA) officials were paid to speed up the approval of generic 
medicines, many pharmacists lost confidence in generics themselves and 
decreased generic substitution on prescriptions (Gupta, 1996). However, ten 
years later in a 2006 survey of 425 physicians in the USA, 78% favour 
substituting generics for brand-name drugs in most cases with five per cent who 
say it is never appropriate to substitute a generic for a branded drug. Doctors 
feel confident that they have the correct information to make an informed 
decision and to discuss this with their patients. The AARP (2006) report notes 
that 80% of the doctors surveyed receive weekly visits by representatives of 
brand-name manufacturers and 75% of these doctors have never received a 
visit from a generic drug representative (AARP, 2006). Pressure to prescribe 
generics come from patients themselves or medical schemes. 
2.6 Branding and Brand Loyalty 
Attributes and benefits are an integral part of the overall levels of meaning of a 
brand (Kotler, 2003: 418). However, they are the most important for consumers 
with regard to medicines. Keller (2000) states that "What distinguishes a brand 
from its unbranded commodity counterparts is the consumers' perceptions and 
feelings about the product's attributes and how they perform". 
A patent may run for 20 years during which time the originator drug is the only 
brand on the market and has a unique opportunity to position itself in the 
consumers mind. The attributes and benefits of that drug once a patent expires 
does not change. However, the factor that does change is that the consumer 
now has the choice of the same attributes and benefits but at a lower price. 
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Brand loyalty is not very strong among patients whose only interest is in the 
cost savings they may achieve. If the patient is made aware that a generic will 
give them exactly the same benefits as a brand-name drug at a lower cost they 
will more likely change to the generic. The reason for the lack of brand loyalty 
is that drugs normally compete with each other on their functional attributes and 
not emotional attributes. The functional attributes which concern the 
pharmaceutical companies are (Suchanti, 2005): 
• Efficacy - the drug has the ability to prevent or cure an illness. 
• Safety - the drug is safe to use with no side-effects. 
• Convenience - it is easy/pleasant to take with regard to dosage 
requirements. 
• Cost-effectiveness - the drug is affordable. 
Customers emotional and spiritual values 
addressed 
Functional and / or emotional benefits 
provided to customers 
Features that must be demonstrated to 
customers - functional benefits 
More powerful 
the brand and 
most difficult to 
imitate but 
hardest to deliver 
Easiest to deliver 
but weaker the 
brand and more 
easily imitated 
Figure 2.6 Brand Value Pyramid (adapted from Davis 2000) 
Davis (2000) states that the higher up the pyramid a product is, the stronger the 
brand recognition, the harder it is to imitate and therefore, less competition 
occurs. The lower a product is down the pyramid, the weaker the brand and the 
easier it is for generics to enter the market. The emotional attributes are rarely 
promoted in drugs although there have been exceptions which are referred to 
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as 'blockbuster' drugs (e.g. Prozac and Viagra). For a product to succeed 
these days, companies must prove that the drug is innovative compared with 
potential branded and generic competition. Due to the high profits obtained 
from patent drugs, pharmaceutical companies have concentrated more on 
patenting than on creating brand loyalty. Although profits are not the only 
reason behind patenting this is regarded by the pharmaceutical industry as an 
essential component of their business model, as seen by the vigorous way in 
which they promote and protect intellectual property rights. 
2.7 Strategies To Protect Patent of Brand-Name Drugs 
A brand-name drug is patented from the time of first research and development. 
The total time can be as high as 20 years. During this time no generic may be 
introduced onto the market in competition with the brand-name drug. If the 
figures reported in the Tufts Centre for the Study of Drug Development (see 
Figure 2.4) are a true reflection of costs it is not surprising that pharmaceutical 
companies have come up with strategies to prolong or prevent the introduction 
of generics once patents expire. In the case of GlaxoSmithKline, their patented 
drug Zantac (an anti-ulcer drug) was worth approximately two to three thousand 
pounds in profits to them for every single day that it lasted (Graham, 2001). 
Three of the most common strategies to prolong the introduction of generics are 
(Pearce, 2006): 
• Pre-emptive launch of generics. A pharmaceutical company is allowed to 
introduce their own generic before the patent expires on their own brand-
name drug (this is called an 'authorised' generic or 'ultrageneric'). This may 
be done under license by another company on their behalf or through a 
subsidiary. This 'ultrageneric' is often launched on the same day as the first 
generic competitor ensuring that profits for the originator manufacturer are 
maximised by claiming market share for the generics too. Introducing two 
identical generics effectively cancels the first six months exclusive rights 
normally due to the first generic. Another benefit of a brand-name 
manufacturer producing their own generic is that they have the ability to 
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market a generic drug by offering to supply it at a reduced rate for a specific 
contract period which usually goes beyond the patent expiry date. Although 
losing on profits from the brand-name drug they halve their competitors 
profits and lock in patients with their generic at a higher price. 
• Layering innovation. This is created by layering patents one upon another 
by patenting an innovation on a base product to maintain the patent. This 
results in an 'enhanced product' by means of alterations in the active 
ingredients, strength, dosage form, route of administration etc. 
• Line extensions. This involves changing the use or extending the use into 
another market e.g. Merck's prostate drug Proscar® was remarketed to help 
hair loss in men, under a new name Propecia® (Pearce, 2006). This saves 
the patent and creates a new additional market with increased profits. 
Another example is GlaxoSmithKline's (GSK) Zyban® which was originally 
developed as an antidepressant drug. However one of the side effects 
noticed was that the nicotine craving diminished when taking it and patients 
gave up smoking. It has since been remarketed as a drug used in nicotine 
dependence. 
2.7.1 Porters Five Forces 
Porter's Five Forces model is an important tool for analysing an organisation's 
industry structure which is essential when making strategic decisions. In the 
traditional economic model, competition among rival firms would normally drive 
profits down. However, competition is never perfect and companies do not sit 
back passively and allow this to happen but rather try to find a competitive 
advantage over their rivals (Thompson, 2001). 
As patents expire and generics reduce the profits of pharmaceutical companies, 
diverse innovation is required. The success of biotechnology in recent years 
(Schmid et al., 2002) has forced the pharmaceutical companies to be proactive. 
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According to the Biotechnology Industry Organisation (BIO), pharmaceutical 
companies increased their licensing and investment deals within the 
biotechnology industry in 2004 by 44% compared to 2003 (Frost and Sullivan, 
2005). This strategy of forming alliances is important for the pharmaceutical 
companies to maintain their large (and sometimes unjustifiable) profits. Figure 
2.7 shows that although the pharmaceutical industry is highly competitive and 
profitable, there are other forces that affect and influence their decisions. The 
Power of the Buyers is weak as they have no bargaining power compared to the 
Power of the Suppliers who are few in number making it difficult for consumers 
to shop around for an alternative and cheaper medicine. 
Barriers to entry 
'Mega' companies -
patents 
High costs of R&D 
Economies of scale exit 
Strict government 
regulations 
Power of suppliers 
• Few suppliers, therefore not easy to switch 
• Suppliers can go for forward integration 
Industry Competition 
• Highly competitive due to 
high profits 
1 
Power of buyers 
End consumers do not have bargaining 
power i.e. no influence on price 
Brand loyalty more in the hands of the 
prescriber (doctor) 
Buyers fragmented 
Threat of Substitutes 
Very few substitutes for 
medicines 
Biotechnology threat to synthetic 
pharmaceutical products 
Figure 2.7 Porters Five Forces for the pharmaceutical industry 
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2.8 Me-Too Drugs 
Generics, which are chemically equivalent to patented brand name drugs, are 
not the only form of competition to the original drug. A patent may be taken on 
a new drug within a particular class which is slightly different and is marketed as 
having a better therapeutic effect or a different mechanism of action. These 
drugs are called 'Me-too' drugs and are usually just as expensive or marginally 
lower in cost than the original class drug. An example of this are Angiotensin-
Converting Enzyme (ACE) inhibitors where numerous 'Me-too' drugs exist e.g. 
Captopril, Enalapril and Lisinopril. There are usually more "Me-too' drugs the 
more prevalent a disease and manufacturers hope that these drugs will capture 
part of a lucrative market. However, many of these drugs have no extra benefit 
and are at best equivalent in efficacy, but more expensive than the original drug 
(Garattini, 1997). Me-too drugs are also taking the place of the cheaper cost 
effective generics within that class. 
2.9 Government initiatives for low income earners 
The Government introduced the Government Employees Medical Scheme 
(GEMS) in January 2006 for low income workers who are employed in public 
service. The scheme is 75% - 100% subsidised by Government, depending on 
annual salary. The lowest package on this scheme offers essential day-to-day 
benefits. The scheme now has 50 000 members, 40% who were previously not 
covered by any medical scheme. These people are now not eligible for free 
state care and their membership has helped reduce patient load at Government 
hospitals (Erasmus, 2006B). However, not everyone is happy with the GEMS. 
Unions feel this is another way of privatising healthcare and of downgrading the 
public health system (Bell, 2006). 
According to a survey conducted in 2005 by the Low Income Medical Schemes 
(LIMS) Committee, low income households with no cover spend on average 
R105 per month on private General Practitioner (GP) visits (Erasmus, 2006A). 
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The survey also found that only 12% of individuals earning between R2 501 and 
R6 000 were covered while 20% earning between R4 501 and R6 000 were 
covered. GPs, medicines, dental services and optometrists were found to be 
high on the preference list of low income households. It was felt that if 
premiums were equal to their 'out-of-pocket' expenses low income earners 
would join a LIMS. Means of reducing premiums further could include employer 
subsidies, treasury subsidies, reduction of health care benefits and a reduction 
in the actual cost of healthcare (Erasmus, 2006A). 
The LIMS is in effect a form of Social Health Insurance (SHI) as contributions 
from individuals, employers and even government would be included. This 
nation-wide medical insurance scheme would be for all employed people based 
on their ability to pay (using a sliding scale). The uninsured would benefit as 
they would be entitled to the standard health care in the public sector which is 
now better funded. Those who are insured would have various levels of health 
care packages available to them including private health care at an extra cost. 
However, this is also a step closer towards Government introducing a National 
Health Insurance Scheme (NHIS). This scheme would be financed by tax 
payments and everyone would receive the same level of coverage regardless of 
their ability to pay, their level of taxation or risk factors. A Reform Strategy and 
Approximate Timeline towards the implementation of a NHIS was 
recommended in a report by the Department of Health in 2002 and is shown in 
Figure 2.8 (Department of Health, 2002). 
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Phase 1: Development of Enabling Environmnet 
• Preparation of Public Sector Budget System 
• Consolidation of Medical Schemes Reforms 
• Development of integrated subsidy system 
• Implementation of measures to contain private sector cost increases 
Phase 2: Implement Preparatory Reforms 
• Risk Equalisation Fund for medical schemes 
• Risk adjusted subsidy to medical schemes 
• State sponsored medical scheme 
• Mandatory environment for civil servants 
Phase 3: Implement Statutory Mandates 
• Mandate medical scheme membership for - Medium to large employees 
- High income earners 
• Voluntary contributory environment for low income groups - State sponsored scheme 
- Public Sector Contributory Fund 
Phase 4: National Health Insurance Implementation 
• Central Equity Fund 
• Public Sector Contributory Fund 
Figure 2.8 Reform Strategy and Approximate Timeline (adapted from SA 
Department of Health - Integrated strategy for Health System 
Reform. 2002) 
Phase One and Phase Two have almost been completed, the biggest exception 
being the implementation of measures to contain private sector cost increases 
(Department of Health, 2002). To proceed with Phase Three it is essential that 
premiums to medical schemes are kept low. By revising the formularies and 
realising the cost savings of substituting generics medical schemes can reduce 
their payouts and pass on these savings to their members. 
2.10 Conclusion 
This chapter has given the researcher insight into studies and reports that have 
been conducted on many aspects of generics, brand-name drugs and the many 
ways they affect consumers' perceptions and behaviour. The literature 
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reviewed would indicate that there is the possibility of potential savings and that 
there are some key areas that need to be addressed and improved on. The 
theory of brand loyalty and strategy, including Porters Five Forces were 
discussed. 
The next chapter discusses the methodology and how the research was 
conducted for this study. 
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CHAPTER 3 : METHODOLOGY 
3.1 Introduction 
This chapter details the research methodology used to enable the objectives to 
be addressed. Methodology is the procedures and techniques used to collect, 
store, analyse and present information. In this chapter the methodology 
employed is discussed and a detailed, step by step, explanation on how the 
data was obtained and analysed is included. The methods of data collection 
are discussed with an explanation of the decision taken with regard to the path 
this study followed. 
This study consists of empirical quantitative data which is collected from various 
primary (books and government publications) and secondary sources (reports, 
published summaries and reviews) (see 3.4 Data Collection). Quantitative data 
is used. Quantitative research differs from qualitative research in the following 
ways: 
• Data is usually gathered using more structured research instruments 
• The results provide less detail on behaviour, attitudes and motivation 
• The results are based on sample sizes that are representative of data 
required 
• The research can usually be repeated, given its high reliability 
• Quantitative data is used to make calculations and 
• The analysis of the results is more objective (Saunders et al., 2003: 378) 
In quantitative research variables are identified, measured and a statistical 
model drawn up to evaluate the results of the manipulated data. It is a more 
efficient method of data collection as it uses formal instruments to collect data 
instead of the researcher themselves. The analysis is conducted using discrete 
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data and is in simple mathematical terms involving tables, charts and diagrams. 
(Saunders era/., 2003: 328) 
3.2 Concepts 
3.2.1 Conceptual Definitions 
According to the South African Concise Oxford Dictionary (2005:238) the 
meaning of the word concept is "an abstract idea". Concepts are not tangible 
and represent an object in an abstract form. According to Ghauri and Gronhaug 
(2002: 31), concepts are "the most critical element in any theory because they 
direct what is captured". 
In the context of this study two concepts, 'savings' and 'use' are defined. The 
word savings as defined by the South African Concise Oxford Dictionary 
(2005:1040) is "preventing waste of a particular resource". In this study the 
concept of savings is utilised in reference to the cost of the drugs, the resource 
being money. The word 'use' in the context of 'one could use' as defined by the 
South African Concise Oxford Dictionary (2005:1295) is "one would like or 
benefit from". 'Use' in this study refers to the use of generics over and above 
brand-name drugs. 
An operational definition follows on from the conceptual definitions described as 
it must indicate how the abstract concept will be measured. 
3.2.2 Operational Definitions 
An operational definition is "a set of procedures that describe the activities to be 
performed to establish empirically the existence or degree of existence of what 
is described by a concept" (Ghauri and Gronhaug, 2002). 
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The concept of "savings" is measured by establishing the cost differential 
between the lowest priced originator drug in a specific class to the lowest priced 
generic drug in the same class. The difference between the two will be the 
"savings". The concept of "use" is measured by whether there is a generic 
available for a particular class of drug and whether the consumer would benefit 
from it in terms of the savings. 
3.3 Research Design 
Research design is used to structure the research, and to provide answers to 
questions such as: 
• What kind of sampling will be used? 
• What techniques will be used to gather the data? 
• How will time and cost constraints be dealt with? 
The research process can be described by using the 'Research Process Onion'. 
Saunders et. al. (2003: 83) states that "the research process is like the layers of 
an onion that need to be peeled away before getting to the central issue of data 
collection". The first layer refers to the adopted research philosophy, the 
second looks at the research approach. The third layer examines the research 
strategy while the fourth layer refers to the time lines. The fifth and last layer is 
associated with data collection including sampling. 
Figure 3.1 shows how the researcher conceptualised the research approach to 
be applied in this study in order to come up with the relevant data required to 
answer the research question as well as to arrive at the fulfillment of the 
research objectives. 
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Figure 3.1 Research Process Onion. (Adapted from Saunders et al (2003)) 
This study aims to compare prices of medication required per month for chronic 
diseases by evaluating the cost per month of the daily defined dose in 
conjunction with the single exit price of the drugs. It is a cross-sectional study 
as it reveals a snapshot of this point in time. 
3.4 Sampling 
A census is conducted as data is collected from the entire population and no 
sampling is required (Saunders et al., 2003: 150). The population consists of 
the 25 chronic diseases for which algorithms are available. It was decided to 
include all of the algorithms in the population as many of the drugs required are 
duplicated across diseases (e.g. bronchiectasis and chronic obstructive 
pulmonary disorder). In the case of four of the 25 chronic diseases, no generics 
could be identified, and these , therefore, did not require extensive analyses. 
3.4.1 Inclusion Criteria 
The Chronic Disease List (CDL) as per Government regulations was selected 
for analysis. Only the exact medicine, class of medicines or therapeutic groups 
mentioned in the algorithms are included in this study. Only data pertaining to 
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an adult was collected i.e. only adult dosages and routes of administration were 
recorded. 
3.4.2 Exclusion Criteria 
The two chronic diseases Bipolar Mood Disorder and HIVAids are excluded as 
no algorithms are as yet available. All paediatric drugs and / or dosages were 
also excluded as defined daily doses (DDDs) are determined for adults only. 
Medicines are classified according to their anatomical, therapeutic and chemical 
characteristics (Bennett and Brown, 2003). A specific class of drug is one or 
more drugs which have the same pharmacological effect as each other. Within 
the class there may be sub-sets of classes which differ chemically. If a class of 
drug did not have a defined daily dose (DDD) it was excluded. Combination 
drugs (e.g. a combination of a oral blood glucose lowering drug, metformin and 
sulphonylurea) often, but not invariably, do not have a specified DDD and were 
excluded. An exception was the combination of levodopa and carbidopa. This 
combination has a DDD as levodopa cannot be administered on its own. 
3.5 Data Collection 
Generalised studies throughout the world have been conducted looking at 
potential savings of using generic drugs over brand-name drugs yet no study 
could be found that looked at chronic diseases only. Primary and secondary 
data were collected. Primary data was collected from the gazetted algorithms, 
the South African Medicines Formulary 7th Edition (SAMF, 2005) and the 
Monthly Index of Medical Specialities (MIMS) (May 2006). The online 
Pharmaceutical Blue Book and the World Health Organisation (WHO) 
Collaborating Centre for Drug Statistics Modelling (WHO, 2006) were also used 
for primary data collection. Secondary data was collected using various search 
engines (e.g. Google, PubMed, Elsevier), journals (e.g. Australian Prescriber, 
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British Medical Journal, Clinical Therapeutics) and the Medicines Review 2005 
report and Global Health Watch 2005-2006. 
3.5.1 Primary Data 
Algorithms 
The Council for Medical Schemes is a statutory body established by the Medical 
Schemes Act (1998) to provide regulatory supervision of private health 
financing through medical schemes. The minimum standards of diagnosis and 
treatment for all prescribed minimum benefit conditions have been published in 
the Government Gazette, and are known as treatment algorithms (benchmarks 
for treatment) (Appendix A). A medical scheme may decide what treatment it 
will pay for each chronic condition, but the treatment may not be below the 
standards published in the treatment protocols. The algorithm for each of the 
25 chronic diseases analysed was looked at in order to record the basic 
medication required under government legislation. The steps in the algorithms 
for diagnosis and treatment were followed and the suggested class of 
medicines and / or general treatment were noted per condition (Department of 
Health, 1998A). 
South African Medicines Formulary (SAMF) 
The South African Medicines Formulary is researched and written by members 
of the Division of Clinical Pharmacology, Faculty of Health Sciences, University 
of Cape Town. The purpose of the formulary is to promote safe, rational and 
cost-effective use of medicines available in South Africa, to serve the various 
educational, information and drug regulatory programmes, and to support 
national health planning. It provides therapeutic information on most drugs 
registered in South Africa. The latest edition (2005 7th edition) was used for all 
collection of data. The treatments and class of drugs collected from the 
algorithms were reviewed in the SAMF(2005), and, where a class rather than a 
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specific medicine was stipulated, all available medicines for that condition were 
noted. The medicine's proprietary (trade) name, manufacturing company name 
and presentation e.g. tablets or nasal spray were recorded (SAMF, 2005). 
Monthly Index Medical Specialties (MIMS) 
The May 2006 MIMS was used to identify all generics and branded versions of 
the medicines identified in the algorithms and from the SAMF (2005). Constant 
double checking took place to ensure that no medicines were left out. It should 
be noted that the SAMF (2005) and MIMS (May 2006) do vary in one important 
manner. MIMS receives remuneration from the pharmaceutical manufacturing 
companies that advertise on its pages., while the SAMF does not accept 
advertising or industry support of this nature. The MIMS may not, therefore, 
include generic medicines produced by companies that choose not to advertise 
(MIMS, May 2006). 
Daily Defined Dose 
The daily defined dose (DDD) is the 'assumed average maintenance dose per 
day used for its main indication in adults.' The DDD is available online from the 
World Health Organisation Collaborating Centre for Statistical Modeling website 
(World Health Organisation, 2006). This is a unit of measurement and does not 
necessarily reflect the recommended or prescribed daily dose. However, by 
using the DDD for each specific medicine, a standardised figure is obtained 
which is independent of price and formulation enabling the researcher to 
perform comparisons between classes. The DDD was converted into a monthly 
defined dose by multiplying by 30 for the purpose of this study. The database 
of DDDs was last updated on 11-01-2006 (World Health Organisation, 2006). 
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The Pharmaceutical Blue Book 
The Pharmaceutical Blue Book is published by Pharmaceutical Publishers, a 
wholly owned subsidiary of Alex White and Company and is available via 
subscription online (Pharmaceutical Blue Book, 2006). The Blue Book is 
renowned for supplying the pharmaceutical industry with independent and 
accurate price lists. Information available on the electronic database includes 
new or discontinued products; packet packaging or sizes; manufacturers; 
packing changes and presentation and prices. The single exit price (SEP) 
(excluding VAT) and corresponding quantity were recorded for this study. The 
price file is constantly updated and all effort has been made to collect the latest 
prices (Pharmaceutical Blue Book, 2006). 
3.5.2 Secondary Data 
A literature search was conducted accessing various databases. Searches in 
the Ebsco database were limited to Academic Search Premier, Business 
Source Premier, Newspaper Source, and MEDLINE. Searches in the PubMed 
databases as well as Science Direct and Elsevier were also used extensively. 
These databases contain numerous journal articles that are available for review 
and enable the researcher to determine whether peers have done research in 
the same field as the researcher. Key search words used to search the various 
databases were "generic drugs", "chronic disease and generics", "potential 
savings", "brand-name drugs", "brand loyalty and drugs", "me-too drugs", 
"generic substitution and perceptions" and "reference pricing". 
Different internet websites of educational and government institutions were 
searched with reference to generic drugs, their savings and perceptions. This 
search was carried out utilising search engines Google and Alta Vista. Multiple 
source and time series based secondary data is collected from the book Global 
Health Watch 2005-2006 (Global Health Watch, 2005) and the report Mediscor 
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Medicines Review 2005 (Bester et a/., 2005) . This secondary resource material 
consists of statistics used to create some of the diagrams in Chapter 2. 
3.6 Ethics 
Ethics is not only limited to human subjects of research or to anyone affected by 
the study but also applies to the way the research is reported. As all data 
collected in this study is in the public domain and is easily accessible, ethics 
approval was easily obtained. However, the researcher has a moral 
responsibility to ensure that all data collected and analysed is valid and true 
(Ghauri and Gronhaug, 2002: 18). The strengths of the methods as well as the 
weaknesses must be honestly reported as this can affect the reliability of the 
results . Ethics approval has been received for this study (reference number 
HSS/06771A). 
3.7 Limitations 
A weakness of this study is that it does not allow for any comparison in the 
future for a price change and is a snap shot of the situation now. Another 
weakness is that it is open to human error i.e. syntax mistakes in entering data. 
All effort has been made to check and cross check data entered to ensure that it 
is accurate. Other limitations have already been described, together with the 
methods used to reduce the impact of those limitations on the quality of data 
collected. 
3.8 Analysis of data 
The Primary data collected was collated in an Excel spreadsheet, sorted and 
the monthly medicine acquisition cost - the monthly defined dosage cost -
calculated using the defined daily dose, strength, quantity and single exit price 
(inclusive 14% VAT) (SEPV): 
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30 days = Taken as an average number of days in a month 
SEPV = Single Exit Price inclusive of VAT (14%) 
DDD / strength = Number of tablets/mis required for DDD 
Quantity = Number of tablets or ml in presentation at the SEP 
Monthly defined dosage cost (R) = (SEPV) x 30 (days) x (DDD/Strength)) 
(Quantity) 
Preliminary data cleaning was done whereby the data was checked and 
corrected and any anomalies were reviewed and corrected where appropriate. 
Some of the chronic diseases have very similar treatment algorithms e.g. 
bronchiectasis and chronic obstructive pulmonary disease and are discussed as 
one. A percentage difference in the price between drugs in the same class 
was tabulated and reported. 
In considering the potential costs savings in respect of each algorithm, the 
gazetted version for the private sector was also compared with the equivalent 
applicable in the public sector, using the 2003 Primary Health Care and the 
1998 Hospital level national guidelines (Department of Health, 1998A). 
3.9 Conclusion 
The results from the calculated differences in price indicate that the objective to 
ascertain whether there will be potential savings using generic over brand-name 
drugs has been achieved. This leads to the next chapter where the data is 
analysed, tabulated and graphically represented and the results discussed. 
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CHAPTER 4 : RESULTS AND DISCUSSION 
4.1 Introduction 
In this chapter the results from Excel spreadsheets are analysed and discussed 
with reference to the problem statement and objectives. Data are the "facts, 
opinions and statistics that have been collected together and recorded for 
reference or for analysis." (Saunders et al., 2003: 476). Analysis "is the ability 
to break down data and to clarify the nature of the component parts and the 
relationship between them" (Saunders et al., 2003: 472). 
The nature of the diseases listed by the Council for Medical Schemes', and the 
way in which each of the medicines is used in their management, is not 
described as these factors are irrelevant to the way in which data have been 
collected and presented. 
4.2 Analysis of Tables 
The tables address this study's objectives, which is to determine the number of 
generics available for the treatment of each chronic condition and to establish, 
by means of the single exit price (SEP) and the Defined Daily Dose (DDD) of 
each drug, whether there are price differentials between generic medicines 
themselves as well as between the generic and the brand name drug. 
4.2.1 Addison's Disease 
The CMS algorithm for Addison's disease (also known as adrenal insufficiency) 
is shown in Appendix A. Table 4.1 shows the listing of medicines included in the 
algorithm. 
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Of the three possible medicines listed, two medicines (hydrocortisone and 
fludrocortisone) have no generic equivalents. The third, which could be 
interpreted as either oral prednisolone or prednisone, is available in two and 
three generic versions respectively (in the former case as either tablets or the 
oral liquid formulation). The cost differentials vary considerably, from 29.1% for 
prednisone tablets, to only 2.6% for the prednisolone variant. 
The public sector STG uses the same medicines, except that it specifically lists 
only oral prednisone. In practice though, prednisone and prednisolone (the liver 
activated form) are considered therapeutically interchangeable. 
4.2.2 Asthma 
The CMS algorithm for asthma is complex, and is presented in Appendix A. It 
uses a 'stepwise approach' to treatment depending on the severity of the 
disease. 
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Capsules MR 3mg 
Tablets 10mg 













































































* Please note that strengths differ for the originator and generic brands 
Table 4.2 shows that Steps one and two (Mild Intermittent and Mild Persistent 
Asthma) require inhaled short-acting beta2 agonists and inhaled corticosteroids. 
Out of the six medicines available three (fenoterol, terbutaline and fluticasone) 
do not have any generic equivalents. For the remaining medicines the number 
of generic equivalents range from 3 (salbutamol and budesonide) to 4 
(beclomethasone). 
In steps three and four (Moderate and Severe Persistent Asthma), inhaled long-
acting beta2 agonists or sustained release theophylline are mentioned. The 
number of generic equivalents for the two long-acting betal agonists are zero 
for salmeterol and three for formoterol. Theophylline has six generic 
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equivalents. Step five (Very severe persistent Asthma) includes oral 
corticosteroids in the treatment. Of the five medicines available three 
(methylprednisolone, budesonide and hydrocortisone) have no generic 
equivalent while prednisone and prednisolone have three and two respectively. 
However, prednisolone only has generic versions available. Budesonide 
offered the most expensive option at R766.85 for a month's supply at the DDD. 
Cost differentials between originator and generics range from 97% (prednisone) 
to 16.5% (beclomethasone). Cost differentials between generics only range 
from 54.6% (formoterol) to 2.6% (prednisone). 
The public sector STGs for chronic persistent asthma mention the same classes 
of medicines in most cases. Only salbutamol and fenoterol are included as 
examples of the short-acting inhaled beta-agonists, and ipratropium as the 
inhaled anticholinergic. No anticholinergics are specifically mentioned in the 
CMS algorithm. As shown in the Table 4.2, there is one generic equivalent for 
this preparation. There is no mention, however, in the public sector STGs of the 
long-acting variants of the beta2-agonists, and only budesonide is listed as the 
inhaled steroid. 
4.2.3 Bronchiectasis and Chronic Obstructive Pulmonary Disorder 
The CMS algorithm is labeled as bronchiectasis, but needs to be read together 
with that for the management of chronic obstructive pulmonary disorder 
(COPD), as shown in Appendix A. 
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* Please note that strengths differ for the originator and generic brands 
Table 4.3 indicates that Bronchiectasis treatment follows the algorithm for 
Chronic Obstructive Pulmonary Disease with the exception of the addition of 
antibiotics for the treatment of an infection (see Appendix A). Inhaled Beta2 
agonists (short- and long-acting) consist of five medicines where three have no 
generic equivalents (fenoterol, terbutaline and salmeterol) and the remaining 
two have three generic equivalents each. The number of generic equivalents of 
the remaining five medicines range from 1 (ipratropium bromide) to 14 
(amoxycillin). Amoxycillin has a large number of indications and is a commonly 
prescribed antibiotic (Carrie et al., 2000). The originator for doxycycline 
(Vibraycin) is no longer manufactured. Cost differentials between originator and 
generics range from 97% (prednisone) to 21.2% (ipratropium bromide). Cost 
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differentials between generics only range from 54.6% (formoterol) to 0.1% 
(amoxicillin). 
The public sector algorithm, in essence, mirrors that of the CMS for COPD. The 
same medicines are mentioned - salbutamol, fenoterol or ipratropium as 
inhaled agents, oral slow-release theophylline and oral prednisone. The 
appropriate antibiotics for treatment of infected cases is less well described. 
4.2.4 Cardiac Failure 
The CMS CDL algorithm is an example of a less prescriptive variant, in that six 
different pharmacological groups (see Appendix A) are mentioned, which 
include a total of 27 different medicines. Broadly, this mirrors the equivalent 
algorithm from the public sector STGs. There is, however, a major difference in 
meaning when each mentions a class or even an example within the class. In 
the case of the public sector, it is understood that the provinces will procure only 
one example from that class. In contrast, unless a medical scheme has an 
appropriately implemented formulary system, it will have to reimburse claims for 
any members of the class, regardless of the price. 
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* Please note that strengths differ for the originator and generic brands 
Within the ACE Inhibitor group (see Table 4.4) the number of generic 
equivalents range from 1 (e.g. fosinopril) to 8 (lisinopril). Moexipril is itself a 
generic while three other medicines have no generic available. Cost 
differentials between the originator and generics within this group range from 
95% (captopril) to 11.5% (perindopril). 
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Beta blockers include nine of the 27 medicines, five of which have generics 
available ranging from 1 (sotalol) to 7 (atenolol) and four with no generics. 
Cost differentials within this group range from 96% (propanolol) to 41% 
(bisoprolol). 
Of the remaining medicines only one medicine in the Loop diurectic group has a 
significant number of generics available. Furosemide has seven generic 
equivalents for oral medication and five for parenteral route of administration. 
The cost differentials are 97% and 80% respectively. The remaining three 
medicines in this group have no generic equivalents available. 
Cost differentials between generics range from 58.9% (ramipril) to 0% 
(spironolactone). 
4.4.5 Cardiomyopathy 
Table 4.5 shows that the CMS CDL algorithm for Cardiomyopathy (see 
Appendix A) follows closely to the CMS CDL algorithm for Cardiac Failure. If a 
patient is truly intolerant to ACE inhibitors, hydralazine and isorbide dinitrate 
combination therapy may be considered. Cardiomyopathy differs from Cardiac 
Failure by the inclusion of warfarin, nitrates, vasodilator and potassium 
supplement. The ACE inhibitors, beta blockers, digoxin, diuretics and 
spironolactone were discussed under Cardiac Failure above. 
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Table 4.5 Cardiomyopathy 














































































































































































































































































































' Please note that strengths differ for the originator and generic brands 
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Warfarin does not have a generic. Isosorbide dinitrate has one generic each for 
sublingual tablets and tablets and no generic for the sustained release tablet. 
Potassium chloride and vasodilators both have two generics. The cost 
differentials between the originator and generics across the drugs discussed 
here range from 90% (hydralazine) to 13.4% (potassium chloride). 
The public sector has no specific equivalent algorithm for cardiomyopathy, and 
this is subsumed under the heading of cardiac failure syndrome. 
4.2.6 Chronic Renal Disease 
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* Please note that strengths differ for the originator and generic brands 
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The CMS CDL algorithm mentions four therapeutic groups for the treatment of 
Chronic Renal Disease (see Appendix A). Table 4.6 shows that within the ACE 
Inhibitor group the number of generic equivalents range from 1 (e.g. fosinopril) 
to 8 (lisinopril). Moexipril only has a generic version available while three other 
medicines have no generic available. Cost differentials between the originator 
and generics within this group range from 95% (captopril) to 11.5% 
(perindopril). 
Beta blockers include nine different drugs, five of which have generics available 
ranging from 1 (sotalol) to 7 (atenolol) and four with no generics. Cost 
differentials within this group range from 96% (propanolol) to 41% (bisoprolol). 
Calcium channel blockers mentioned in the algorithm consist of five different 
drugs. The originator drug for lercanidipine is no longer available and isradipine 
does not have a generic. Cost differentials within this group range from 91% 
(nifedipine) to 25% amlodipine). Erythropoietin is mentioned in the algorithm but 
the DDD cannot be determined. The adult dose as indicated in the SAMF was 
used to calculate the amount required for a month. From this calculation an 
approximate cost per month can be determined. 
In contrast, the public sector STGs focus more on acute renal insufficiency, 
mentioning the use of furosemide, the ACE Inhibitor (giving as an example, 
ramipril), the calcium channel blockers (listing verapamil as the example), as 
well as the alpha blocker (e.g. prazosin). The chronic renal failure STG also 
mentions a wide range of complications, such as hyperphosphataemia, 
anaemia (specifically mentioning the use of epoetin alfa {erythropoietin}, but 
stating that this should be prescribed by a specialist only, on a named patient 
basis), hyperparathyroidism, aluminum toxicity and acidosis. In contrast, the 
CMS binds every medical scheme to the provision of an expensive agent, 
stipulating that in cases of iron therapy failure, erythropoietin must be 
reimbursed if the patient's haemoglobin is below eight gm/dl. 
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4.2.7 Coronary Artery Disease 
Hyperlipidaemia, Diabetes Mellitus and Hypertension occur frequently with 
Coronary Artery Disease and these chronic conditions must be managed as per 
the disease-specific algorithm (see Appendix A). Four therapeutic groups are 
mentioned in the algorithm with a total of 19 medicines between them. 
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* Please note that strengths differ for the originator and generic brands 
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As can be seen in Table 4.7 Atenolol had the highest number of generics 
available i.e. seven while seven drugs have no generics available. The 
originator drugs for glyceryl trinitrate and lercanidipine are no longer 
manufactured. Within the nitrates group, glyceryl trinitrate's generic for the 
parenteral route of administration is more expensive than the originator by 11%. 
Cost differentials between all originator and generic drugs mentioned ranged 
from 97% (propanolol) to 18% (isosorbide dinitrate). 
The public sector equivalent can be found under the heading of chronic stable 
angina pectoris, which lists the nitrates, beta blockers, calcium channel blockers 
and aspirin. In the case of the calcium channel blockers, the examples cited are 
the older, off-patent, cardiac selective types, verapamil and diltiazem. In 
contrast, the CMS algorithm calls for the long-acting dihydropyridine type. 
These are often more expensive, and generic equivalence is controversial. As 
the first of these, the long-acting formulations of nifedipine, are listed as non-
substitutable by the Medicines Control Council (Medicines Control Council, 
2006). 
4.2.8 Crohn's Disease 
The CMS CDL algorithm for Crohn's disease (see Appendix A) made mention 
of 13 medicines for the three stages of management: perianal disease, in 
remission and active disease. 
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* Please note that strengths differ for the originator and generic brands 
Table 4.8 shows that only two medicines are listed for perianal disease and they 
have 14 (ciprofloxacin) and 17 (metronidazole) generic equivalents. One 
medicine only (prednisolone) has generic versions while seven do not have any 
generic equivalents at all. The number of generic equivalents for the remaining 
drugs ranged from 1 (mesalazine) to 3 (prednisone). Cost differentials 
between originator and generics ranged from 97% (prednisone and 
metronidazole) to 27% (mesalazine). The cost differential between the two 
generics of prednisolone is 17.2% for syrup and 2.6% for tablets. 
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The public sector STG lists an altogether narrower set of alternatives, ranging 
from the symptomatic (loperamide, codeine phosphate, vitamin and mineral 
supplementation, metronidazole), to simple disease modifying agents 
(sulfasalazine, prednisone - though including the prednisolone sodium 
phosphate retention enemas) and the older antineoplastics (azathioprine, 
methotrexate). 
4.2.9 Diabetes Insipidus 
Table 4.9 shows that there is only one drug (desmopressin) mentioned in the 
CMS CDL algorithm for diabetes insipidus (see Appendix A) and there is no 
generic equivalent. Cost savings cannot be attained. The same medicine is 
listed by the public sector. 
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4.2.10 Diabetes Type 1 
This is a rapidly expanding area of medicine, with new forms of insulin reaching 
the market. These are often of marginal benefit but markedly more expensive. 
An algorithm that doesn't specify the type of insulin to be reimbursed therefore 
places the scheme at risk, unless effective managed care measures (such as a 
formulary) are in place. 
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Table 4.10 Diabetes Type 1 
Insulin 
Ultra fast acting 



















































































All originators as they are not really interchangeable as 1 yeast based and the other bacteria based 
Insulin is the only medicine mentioned for the treatment of diabetes type 1 in the 
CMS CDL algorithm (see Appendix A). Table 4.10 shows that there are five 
different types of insulin: ultra fast -, fast - , intermediate to long - , long acting 
and biphasic. Long acting only has one drug while the remaining insulins range 
from 2 (fast acting) to 5 different drugs (biphasic). However, only one drug for 
ultra fast acting insulin has a generic equivalent. The cost differential between 
the originator and generic is 20%. 
The public sector STG uses the same format, but there, as with the ACE-
inhibitors and beta-blockers, the expectation is of a province-wide, single 
selection made by a Pharmacy and Therapeutics Committee. 
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4.3.11 Diabetes Type 2 
Four therapeutic treatments are mentioned in the CMS CDL algorithm for the 
treatment of diabetes type 2 (see Appendix A). Insulin is one of them and is 
discussed above under Diabetes Type 1. 
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Insulin are all originators as they are not really interchangeable as 1 yeast based and the other bacteria based 
In the other three therapeutic treatments (see Table 4.11), seven medicines are 
mentioned of which three are only available from the originator firm. The 
number of generic equivalents for the remaining four range from 3 (glimepiride) 
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to 7 (gliclazide). Cost differentials between originator and generic ranges from 
95% (glibenclamide) and 17% (metformin). 
The CMS algorithm is vague in the way it identifies the entire sulphonylurea 
class, rather than specific examples within that class. It also, unlike the public 
sector STGs, includes a newer class for which no generics exist. These are the 
thiazolidinediones. 
4.2.12 Dysrhythmias 
The CMS algorithm in this regard is actually a set of three - covering Chronic 
Atrial Fibrillation, Chronic Atrial Flutter and Ventricular Tachycardia. 
Table 4.12 Dysrhythmias 
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* Please note that strengths differ for the originator and generic brands 
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Table 4.12 shows that the generic of digoxin, one of the 14 drugs mentioned in 
the algorithm for dsyrrhythmias (see Appendix A), is more expensive than the 
originator by 3%. Of the remaining 13 drugs five have no generic equivalents 
and seven have generic equivalents ranging from 1 (digoxin) to 7 (atenolol). 
Cost differentials between originator and generics ranged from 97% 
(propanolol) to 19% (aspirin). Cost differentials between generics of the same 
drug ranged from 28% (verapamil) to 0% (amiodarone). The difference in price 
between the highest and lowest priced beta blocker originators is 66%. 
Again, by not identifying specific medicines within a class, the CMS algorithm 
includes more and less expensive variants, whereas the public sector algorithm 
is more specific. It includes only propranolol and atenolol as the beta blockers, 
verapamil as the calcium channel blocker, digoxin, warfarin and amiodarone. 
4.2.13 Epilepsy 













































































































'Originator no longer manufacturered 
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The CMS CDL algorithm for epilepsy (see Appendix A) made mention of 10 
medicines for the two stages of treatment: primary partial seizures and primary 
generalized seizures. Table 4.13 shows that 70% of the medicines have no 
generic equivalents available while one has no originator (phenobarbital). 
Carbamazepine and lamotrigine have three and four generic equivalents 
available respectively. The cost differentials between the originator and 
generics of these two drugs is 75.5% (carbamazepine) and 23.5% (lamotrigine). 
The cost differential between the two generics of phenobarbital is 45.1%. 
Unlike other algorithms, the CMS algorithms for epilepsy is very specific about 
which medicines are to be reimbursed. That said, it does include a number of 
newer, more expensive agents that are not provided for in the public sector 
STGs, which only include phenytoin, carbamazepine, phenobarbitone, sodium 
valproate, ethosuximide and clonazepam. The additional agents are 
lamotrigine, topiramate and oxcarbazepine. As with all other CMS algorithms, 
no justification is given for this deviation from what are considered "essential 
medicines". 
4.2.14 Glaucoma 
Of the 12 medicines mentioned in the CMS CDL algorithm for Glaucoma and 
shown in Table 4.14, only two (timolol and acetazolamide) have a generic 
equivalent. The remaining 10 are all originator drugs. The cost differential 
between the originator and generics is 54.8% (acetazolamide) and 42.9% 
(timolol). 
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Table 4.14 Glaucoma 













































































































* Please note that strengths differ for the originator and generic brands 
The greatest contrast between the CMS algorithm and the public sector STGs is 
again the use of broad classes, in this an example is the statement that topical 
alpha2-agonists, carbonic anhydrase inhibitors or prostaglandin analogues 
should be reimbursed. The public sector starts with the older, and potentially 
cheaper pilocarpine products (drops or gel), and then only includes a beta 
blocker (in this case, only timolol) and a carbonic anhydrase inhibitor 
(acetazolamide). 
4.2.15 Haemophilia 
For Haemophilia A there are three drugs (desmopressin, factor VIII and 
tranexamic acid) mentioned in the CMS CDL algorithm (see Appendix A) and 
for Haemophilia B only one drug (factor IX). Table 4.15 shows that there are no 
generic equivalents for any of these drugs. No public sector equivalent regimen 
exists. 
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Presentation and Strength 
Tablets 0.2mg 




































Statins and fibrates are the only two therapies mentioned in the CMS CDL 
algorithm for hyperlipidaemia. There are seven medicines in total, three are 
only available from the originator firm and one (lovastatin) has no originator 
drug but one generic equivalent as shown in Table 2.16. The number of 
generic equivalents for the remaining three range from 1 (bezafibrate) to 8 
(simvastatin). Cost differentials between the originator and generics range from 
40.4% (pravastatin) to 32.7% (bezafibrate). 
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* Please note that strengths differ for the originator and generic brands 
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The equivalent public sector STG is labeled as dyslipidaemias, and is vague to 
the point of not mentioning anything other than that the "Principles of drug 
treatment" include "the rational use of hyperlipidaemic drugs - efficacy, proven 
effects, cost, side effects, additional benefits and comparisons" and that 
"classes of drugs to be used singly or in combination". According to the 
Department of Health (1998a), four million people in South Africa in 1998 had 
untreated hyperlipidaemia. Given the prevalence of this condition, considered 
an important contributory factor to deaths from coronary heart disease and 
strokes in the South African population, this is a remarkable omission 
(Department of Health, 1998A). 
4.2.17 Hypertension 
ACE Inhibitors, beta blockers and calcium channel blockers are discussed 
under Chronic Renal Disease section 4.2.6. Diuretics are discussed under 
Cardiac Failure in section 4.2.4. 




































































Injection 10mg/ml / 
20mg/2ml* 
Tablets 10mg 














































































































Table 4.17 Hypertension continued. 





































































































































Tablets SR 240mg 
Tablets 60mg 





































































































































* Please note that strengths differ for the originator and generic brands 
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As shown in Table 4.17 there are six drugs within the angiotensin-receptor 
blockers group and two drugs in the alpha-blocker group mentioned in the 
algorithm for Hypertension (see Appendix A). None of these drugs have a 
generic. The cost differentials between the originators and generics of all 
therapeutic groups range from 97.4% (furosemide) to 11.5% (perindopril). 
As with a number of other algorithms (notably for diabetes), the CMS algorithm 
only mentions classes, not specific medicines within those classes. The most 
notable difference between this and the equivalent public sector STG is the 
inclusion of the angiotensin-receptor blockers (ARBs), for which no generics are 
available. No motivation is given for the inclusion of the ARBs in the table (see 
Appendix A) of co-morbid conditions, where at times they appear as alternatives 
to ACE inhibitors and at times do not. ARBs are listed as alternatives to ACE 
inhibitors in patients with diabetes but not other co-morbid conditions. 
4.2.18 Hypothyroidism 
Table 4.18 shows that there is only one drug (levothyroxine sodium) mentioned 
in the CMS CDL algorithm for Hypothyroidism (see Appendix A) and there is no 
generic equivalent. The same medicine is prescribed in the public sector STG 
for this condition. 
































4.2.19 Multiple Sclerosis 
The CMS CDL algorithm for multiple sclerosis made mention of eight medicines 
for various stages of management (See Appendix A): symptomatic, acute 
relapse and frequent relapse. 














































































































* Please note that strengths differ for the originator and generic brands 
Table 4.19 shows that of the six medicines listed for symptomatic management, 
all had a least one generic equivalent. The number of generic equivalents 
ranged from 1 (baclofen) to 4 (oxybutynin). In one case (morphine IV) only 
generic versions were available. Cost differentials between originator and 
generics ranged from 85% (imipramine) to 4.6% (morphine). However both 
single medicines listed for relapse were available from only the originator firm. 
Of these, beta interferon represented the most expensive option. 
This condition is not included in the public sector STG/EDLs. 
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4.2.20 Parkinson's Disease 
This CMS algorithm (see Appendix 2), unlike many others, is notable for not 
including a number of new treatments that are available for this distressing 
condition (such as entacapone and tolcapone). Instead, it broadly mirrors the 
public sector STG, which lists benzhexol, orphenadrine, levodopa/benserazide 
and levodopa/carbidopa. 


















































































* Please note that strengths differ for the originator and generic brands 
Of the seven medicines mentioned in the CMS CDL algorithm for Parkinson's 
disease, only two (admantane and combination carbidopa and levodopa) have 
a generic equivalent as shown in Table 4.20. The remaining five are all 
originator drugs. The cost differential between the originator and generics is 
53.8% (adamantine) and 20% (carbidopa / levodopa combination). 
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4.2.21 Rheumatoid Arthritis 
Table 4.21 Rheumatoid Arthritis 




































































































































Dispersible Tablets 20mg 
Tablets 20mg 
Tablets 400mg / 200mg* 
Tablets 250mg 
































































































































* Please note that strengths differ for the originator and generic brands 
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The CMS CDL algorithm for rheumatoid arthritis mentions three therapeutic 
groups for the treatment of this disease (see Appendix A): non-steroidal anti-
inflammatory drugs (NSAID), corticosteroids and disease modifying anti-
rheumatic drugs (DMARD). Table 4.21 shows that of the 12 medicines listed for 
NSAIDs, four have no originator drugs but only generic equivalents (e.g. 
piroxicam), three have no generic equivalents (e.g. ketorolac) and the remaining 
five have both originator and generic equivalents with the number of generics 
ranging from 1 (ketoprofen) to 11 (diclofenac sodium). Corticosteroids all have 
generic equivalents except for one (methylprednisolone) while one 
(prednisolone) does not have an originator but two generic equivalents. Within 
the DMARD group only one drug (azathioprine) has generic equivalents out of 
the five drugs mentioned in the algorithm. Of these five drugs, penicillamine 
offered the most expensive option. The cost differentials between the originator 
and generics for all groups ranged from 97% (prednisone) to 48.9% (diclofenac 
sodium). 
The CMS algorithm includes only one of the newer agents in this field, 
leflunomide. Even this agent, which has no generic equivalent, is not included in 
the public sector STG. This only lists paracetamol (with or without codeine 
phosphate), indometacin or ibuprofen as the NSAID examples, and then 
chloroquine, sulfasalazine, azathioprine and methotrexate as the DMARDs. A 
range of steroids (e,g, prednisolone) are also provided for in this STG. 
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4.2.22 Schizophrenia 
Table 4.22 Schizophrenia 
Antipsychotic 






































































































Tablets 1 mg 
Tablets 5mg 
Tablets 1mg 
Injection depot 20mg/ml 
Tablets 10mg 
Injection depot 20mg/ml 
Capsules 50mg 
































































































































Of the 21 medicines mentioned in the CMS CDL algorithm for Schizophrenia, 
10 are only available from the originator firm (see Table 4.22). The maximum 
number of generic equivalents available for the remaining medicines is two (e.g. 
clozapine). Cost differentials between the originator and generics ranged from 
94.2% (prochlorperazine) to 27.8% (clozapine). 
As with many others, the CMS algorithm for this condition makes use of very 
wide descriptors of medicine classes - typical antipsychotic or atypical 
antipsychotic, mood stabilizer and antidepressant. This places a medical 
scheme at increased risk of exposure to claims for newer, patented products 
which may not offer a clinical advantage. 
In the public sector STG, in contrast, a very limited range of medicines is 
included: haloperidol, lorazepam, zuclopenthixol, chlorpromazine, fluphenazine, 
flupentixol decanoate, and, for the management of extrapyramidal side effects, 
biperiden. 
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4.2.23 Systemic Lupus Erythematosus 
All of the drugs mentioned in the CMS CDL algorithm for systemic lupus 
erythematosus are also mentioned in the CMS CDL algorithm for rheumatoid 
arthritis (see Appendix A). 



























































































Presentation and Strength 
Tablets 400mg/200mg* 
Tablets 250mg 












































































































































* Please note that strengths differ for the originator and generic brands 
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Table 4.23 shows that the cost differentials between the originator and generics 
for all groups ranged from 97% (prednisone) to 48.9% (diclofenac sodium). 
The equivalent public sector algorithm is far more restrictive, mentioning only 
prednisone, azathioprine, cyclophosphamide and chloroquine. 
4.2.24 Ulcerative Colitis 
There are only three therapeutic groups of medicines mentioned in the 
ulcerative colitis CMS CDL algorithm for the treatment of the two stages of the 
disease: proctosigmoiditis and extensive colitis. 
Table 4.24 Ulcerative Colitis 
5-aminosalicyclic 
































































































































* Please note that strengths differ for the originator and generic brands 
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Table 4.24 shows that the three therapeutic groups consist of 11 medicines of 
which seven have no generic equivalents. One drug (prednisolone) has no 
originator but two generic equivalents. The number of generic equivalents for 
the other three medicines range from 1 (mesalazine) to 3 (azathioprine). The 
cost differential between the originator and generics of prednisone is high at 
97% while the lowest cost differential is 27% (mesalazine). 
The public sector STG is presented as for Crohn's disease. 
4.3 Discussion 
The results presented above need to be placed in the context of the entire 
market. The relative contribution to beneficiaries payments of each of the 
chronic diseases provided for in the Prescribed Minimum Benefits is known 
from the annual report produced by the CMS (see Introduction), but more 
accurate figures on the numbers of patients receiving each medicine mentioned 
in the CMS CDL algorithms are, at this stage, not easily accessible. Modeling 
the possible impact of greater degrees of generic substitution is thus not easy. 
Across all medicines supplied to medical scheme members, some indication of 
generic penetration of the market can be gleaned from individual medical 
scheme administrators' reports. For example, Mediscor has reported that, in 
2005, the generic utilization rate increased to 43.7% (from 40.2% in 2004) in 
volume terms (Bester er a/., 2005). In 2000, generic medicines made up about 
30% of the value of global sales of medicines. While in value terms generic 
penetration was noted in that report to be higher in some developing countries 
(e.g. 71% in Bangladesh, based on 2000 data), in volume terms South Africa 
would seem to be approaching a global maximum (World Health Organisation, 
2004). Although the data are somewhat dated, it is notable that a generic 
utilisation rate, in volume terms, of just under 50% seems the most that can be 
achieved, across a range of health system designs (WHO, 2004). The WHO 
World Medicines Situation (2004) reported that, based on 1998 data, generic 
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utilisation by volume was 45% in the United States, 47% in the United Kingdom 
and 40% in Canada. That this was the result of deliberate policy stances and 
interventions was also clearly demonstrated by the rank outlier in this regard; in 
1996 only 3% of prescription volume in France was for generic medicines 
(WHO, 2004). 
4.3.1 Chronic Diseases with no generics available 
It would seem that those conditions on the CMS CDL which account for a very 
low percentage of total CDL gross costs, suggesting a very low prevalence 
within the population, do not attract a large number of generic competitors. In 
such cases, no generic-friendly policy can result in cost saving by the patient. 
The diseases that fall within this category were: 
(a) Diabetes Insipidus - this disease is ranked 26 (out of 27) according to the 
percentage of total Chronic Disease List Cost, Quarter 4 2005 while the 
percentage prevalence of diabetes insipidus is the second lowest with 
0.003% of the population infected. There are no generics available and 
the gross cost per patient per month is an average of R370. 
(b) Haemophilia - is ranked 23 out of 27 according to the percentage of total 
Chronic Disease List Cost, Quarter 4 2005 with the percentage 
prevalence the lowest with 0.0002% of the population infected. However, 
the gross cost per patient per month based on the DDD methodology is 
approximately R20 000, which is ten times the next highest cost for a 
disease (multiple sclerosis) on the CDL. This is an artefact of the DDD 
methodology, as the quantity used for utilisation research bears little 
resemblance to a clinically relevant dose for this indication as discussed in 
section 3.5.1. 
(c) Hypothyroidism - although ranked 11 out of 27, the cost per patient per 
month (R37.02) is small while the prevalence is relatively high at 1.4% of 
77 
the population. There are no generics for the drug of choice, which is 
levothyroxine sodium. 
Table 4.25 Chronic disease ranked according to the percentage of total 
CDL cost and their prevalence, Quarter 4 2005. (adapted from 




Diabetes Type II 
Asthma 
Diabetes Type 1 
HIV/AIDS 
Coronary artery disease 
Epilepsy 












Bipolar mood disorder 
Crohn's disease 
Haemophilia 





























































A mean cannot be weighted against prevalence as no strong reliable data 
exists. The data from Mediscor Medicines Review (Bester et al., 2005) is 
obtained by analyzing claims processed by the Mediscor Pharmaceutical 
Benefit Management (see Table 4.25) . The data supplied in the latest Council 
of Medical Schemes Health Report (2006) should be used with caution. The 
Report states "There were other concerns with this data. For instances, during 
2005 certain schemes reported as much as half the cases seen in 2004; in 
some cases this was due to a change in definitional criteria for chronic 
diseases. This data should therefore be interpreted with great caution" (Council 
for Medical Schemes, 2006). In light of this the median of cost differentials was 
used to produce graphs for the discussion. 
4.3.2 Cost differential median between originator drugs and generic 
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Figure 4.1 Cost differential median between originator and generic 
equivalents per chronic disease. 
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The median of the cost differentials between originator and generic equivalents 
was calculated for each disease and is shown in Figure 4.1. Three of the 
diseases stipulated did not have any medicines with generic equivalents to 
compare (see 4.3.1). The median cost differential of the remaining 22 chronic 
conditions ranges from 19.5% for Type 1 diabetes mellitus to 97% for Addison's 
disease although only one generic equivalent was available for each. Taking 
the cost differentials throughout the whole range of chronic diseases the overall 
cost differential median is 49.9% (22 diseases, 80 drugs with generic 
equivalents). This could be interpreted as meaning that, by using generics, the 
patient has the potential to save up to 49.9% on the cost of medicines (inter 
quartile range 32 to 78.5%). Such an interpretation ignores the prevalence of 
each condition. Accordingly, it does not correspond to that reported by Djolov 
(2003), who used an arithmetical view and sales value of the top 200 selling 
drugs to determine potential saving. A previous study by Karim et al. (1996) 
showed a savings of only 6.8% by substituting generics for prescribed drugs. In 
addition to the consideration of the differences in methods employed, 
interpretation of these results must take into account the contribution of a 
variety of factors, including: 
• patent expiries and new generic entrants in recent years 
• changes in the policy environment, especially since 2003, when an offer 
of generic substitution became mandatory 
• changes in medicine pricing practices since the single exit price became 
applicable in 2004. 
Karim et al. (1996) felt that restrictive prescribing and dispensing practices 
resulted in the low cost differential. However, this study, by using the SEP of 
the drug per chronic condition shows potential savings ranging from 0% to as 
much as 97% before it moves along the distribution chain. 
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Figure 4.2 Median of the cost differential between generic equivalents per 
chronic disease. 
The median cost differential of only the generic equivalents per chronic disease 
was calculated. Six of the chronic diseases did not have more than one generic 
to compare. Figure 4.2 shows that the cost differentials median of the 
remaining 19 diseases range from 0% (see Table 4.26) to 90% (aspirin -
Coronary Artery Disease ). Taking the cost differentials of only generics 
throughout the whole range of chronic diseases gives an overall cost differential 
median of 9.2% (19 diseases, 74 drugs with more than one generic equivalent) 
(inter quartile range from 1.38 to 21.6%). 
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• Originator and generics • Generics only 
Figure 4.3 Median of the cost differential between originator and generic 
equivalents vs. median of the cost differential between generics 
only. 
Figure 4.3 shows that the median cost differentials between originators and 
generics are greater than the median cost differential between generics only. 
To some extent, this may be explained if one accepts the argument made by 
industry-friendly analysts (DiMasi ef a/., 2003). According to this approach, the 
higher cost of innovator medicines is explained by the cost of research and 
development and the need to recoup this expense. Even if this argument is 
accepted, it is difficult to understand that such amortization has not occurred by 
the time the patent expires and generic competitors reach the market. A 
continued price differential after patent expiry to some extent reflects the 
residual brand loyalty attached to a product, and thus the premium consumers 
are willing to pay for that particular brand (Pearce, 2006) . To some extent it 
also reflects continued costs of marketing such a brand aggressively. That a 
smaller cost differential exists between generic competitors is easier to explain, 
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as these are differentiated in the market largely on the basis of cost. Input costs 
in this segment of the market are also expected to be more similar, and 
competition would result in margins that are closer to one another. This may, on 
the other hand, point to anti-competitive behaviour in this market. There are 
cases throughout the 25 chronic diseases where the cost differential of the 
generic equivalent for a particular drug is between 0 and 1% (see Table 4.26). 
This points to the possibility of price collusion between generic producing 
companies. 
Table 4.26 Cost differential of between 0 and 1% of generic equivalents. 
Drug 
Amoxicillin capsules 500mg 
Doxycycline Tablets 100mg 
Enalapril Tablets 20mg 
Ramipril Capsules 10mg 
Ciprofloxacin Tablets 500mg 
Metronidazole 500mg/100ml 
Glimepiride Tablets 4mg 
Amiodarone Tablets 200mg 
Pravastatin Tablets 40mg 
Indapamide Tablets 2.5mg 
Spironolactone Tablets 25mg 
Oxybutynin Tablets 5mg 
Sulpiride Capsules 50mg 
Clozapine Tablets 100mg 
Clomipramine Tablets 25mg 
Dosulepin Tablets 75mg 
Cost differential 

















The Department of Health (DOH) is planning to introduce an international 
benchmarking exercise in 2007. Innovator products will be compared with their 
exact equivalents in four comparator markets (Canada, Australia, New Zealand, 
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Spain). South African prices will not be allowed to exceed the lowest price 
available in this basket of countries. Thereafter, generic prices will be 
compared, and will be required to be at least 40% less than the innovator price. 
This may have the adverse effect of setting a price floor, rather than a ceiling, 
as competitors set prices that meet, but do not necessarily exceed, the 
benchmark. 
Competition theory would seem to support a contention that the cost differential 
between the innovator and the lowest priced generic would be related to the 
number of generic equivalents in the market. It is received wisdom in this field 
that the maximal cost differentials are only achieved when at least nine products 
are in the market (Gray, A. pers. comm.). In order to test this contention, within 
the narrow sample of medicines used in the management of chronic conditions, 
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Figure 4.4 Percentage cost differentials vs. number of generic equivalents 
available. 
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Figure 4.4 shows that there are many originators with one or two generic 
equivalents with price differentials below 60%. It does seem, at least visually, 
that the greater the number of generic equivalents, the higher the cost 
differential. The correlation coefficient is, however, not entirely convincing, at 
only 0.49. There are examples of high cost differentials in highly competitive 
areas of this market - for example, metronidazole has 17 generic equivalents 
with a cost differential of 96.9% (see Table 4.27). There are exceptions. Drugs 
with a small number of generics may occasionally display high cost differentials 
(imipramine has one generic equivalent with a cost differential of 85.4% - see 
Table 4.19). 










































































































































Table 4.27 shows that the median cost differential for the total number of drugs 
with generic equivalents is 49.9% (inter quartile ranges from 34.1 to 81) and the 
mean is 55.4%. Sixty-seven percent of all cost differentials between originator 
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and generics are greater than the Department of Health's proposed 40% 
benchmark. The setting of this low benchmark may lead to an increase in the 
price of generics as manufacturers may use the 40% as the highest and not 
lowest cost differential allowed. 
4.4 Conclusion 
This chapter analysed and presented the information of the data gathered by 
means of tables and graphs. The results show that there are large cost 
differentials between originator drugs and their generic equivalents and smaller 
cost differentials between generics themselves. The results and analysis of the 
above will aid in making recommendations in the next chapter on how to 
improve potential cost savings in chronic diseases. 
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CHAPTER 5 : RECOMMENDATION AND CONCLUSION 
5.1 Introduction 
This study assesses the potential savings of substituting generics for brand 
name (originator) drugs within the chronic disease algorithms as set out by the 
Council for Medical Schemes. The study begins with the research idea which 
generated a problem statement. Chapter One outlines the framework of the 
study and objectives were set. The main objective critical to this study was to 
determine whether there was the potential for cost savings by looking at the 
number of generics available for the treatment of each chronic condition and to 
establish, by means of the single exit price (SEP) and the Defined Daily Dose 
(DDD) of each drug, whether there are price differentials between the generic 
and the brand name drug as well as between generic medicines themselves. 
Chapter Two discusses the current literature with reference to other research 
that has been conducted pertaining to the study. An insight into how other 
people have approached their research was also discussed. A look at the 
current situation in South Africa today with regard to generic substitution and 
cost savings was included. Chapter Three looks at the research methodology 
used to meet the objective and the reasoning behind the use of specific data. 
Chapter Four is the presentation and analyses in tabular and graphical form of 
the data obtained from the Pharmaceutical Blue Book, the SAMF, the MIMS, 
the DDDs and the Algorithms. From these chapters recommendations to 
promote cost savings are proposed. 
5.2 Strategies to lower the cost of medicines 
It has been argued that the pricing section of the National Drug Policy was not 
well developed in 1996 (Gray and Matsebula, 2000). The aim of the policy was 
clear enough - "To promote the availability of safe and effective drugs at the 
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lowest possible cost". How this was to be achieved was less clear. The policy 
document was less developed in respect of how prices would be controlled or, 
at least, how downward pressure on prices would be exerted apart from the 
introduction of "transparency". Some sort of reference pricing was envisaged, if 
not spelled out in detail. In fact, the State was committed to an intervention 
which has not been realised: 
• "Where the State deems that the retail prices of certain pharmaceuticals 
are unacceptable and that these pharmaceuticals are essential to the 
well being of any sector of the population, the State will make them 
available to the private sector at acquisition cost plus the transaction 
costs involved." (Department of Health, 1996). 
The generic policy was more simply stated: 
• "The availability of generic, essential drugs will be encouraged through 
the implementation of incentives that favour generic drugs and their 
production in the country." 
• "The policy will aim at achieving generic prescribing in both the public 
and private sectors. Until this aim is achieved, generic substitution will be 
allowed, through legislation, in the public and the private sector. It will be 
incumbent on the pharmacist, prior to dispensing a prescription, to inform 
the patient on the benefits of generic substitution and to ensure that 
substitution takes place with the patient's full understanding and 
consent." 
• "Patients have the right to make informed decisions concerning their own 
health, including a choice for generic drugs." 
• "A regularly updated list of products that cannot be substituted will be 
prepared and disseminated by the MCC." 
(Department of Health, 1996) 
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Although no specific industrial policies have emerged, the concept of mandatory 
offer of generic substitution has been enshrined in South African law, and 
patients' rights to an informed choice have been preserved in this system. The 
Medicines Control Council has produced two versions of the non-substitutable 
list, but is at present reconsidering this issue. 
However, the aims of the NDP have not been fulfilled and much more can be 
done by Government to promote the availability of cheaper generics by 
implementing price controls, encouraging the production of generics and 
reviewing their policies. 
5.2.1 Price Controls 
While it is true that the cost of a medicine increases the further it moves along 
the distribution chain, all links in that chain need to be addressed if any price 
intervention is to be effective. The situation in South Africa is, at the present 
time, somewhat confusing. Virtually all links in this chain, from wholesalers to 
managed care drug distributors and pharmacies, are profiting before the generic 
medicines reach the patients. It may well be that consumers only receive a 
fraction of the cost differential found in this study for a particular medicine. The 
South African Government has, over the past three years, attempted to 
introduce a complex set of dispensing fees. Even at this late stage, there are 
statements that the livelihoods of pharmacies are in question, as they cannot 
make enough profit from the dispensing fee stipulated and that, therefore, many 
will face closure (Minister of Health and Another v New Clicks South Africa (Pty) 
Ltd and Others, 2005). It is stated that this is especially problematic in rural 
areas where easy access to medicines will be compromised. 
Less controversial, but particularly effective, has been government's 
intervention in relation to the ex-manufacturer cost of medicines, the single exit 
price. When initially introduced in 2004, the pricing regulations required 
manufacturers to set their single exit prices at the weighted mean of all private 
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sector prices in 2003, taking into account all discounts and rebates offered at 
that time. Comment has recently been invited in the next step in the process. 
Draft Regulations were published on 1 December 2006, providing for a 
"Methodology for International Benchmarking of the Prices of Medicines and 
Scheduled Substances in South Africa". It is proposed that innovator products 
be compared, product by product, with their exact equivalents sold in Australia, 
New Zealand, Canada and Spain. The South African price will not be allowed to 
exceed the lowest price from that basket of countries. The relevant section of 
the proposed methodology for generic medicines reads as follows: 
"The benchmarking will be done one month after the SEP has been published 
for the originator medicines. The South African ex-manufacturer price shall be 
used as a basis for benchmarking. The benchmark price (ex-manufacturer) for 
generic medicines shall be at least 40% lower than the ex-manufacturer of the 
originator medicine. The benchmark price will become the new maximum 
manufacturer price." (Medicines and Related Substances Act, 2006). 
There is the risk that, in the absence of strong competition in a particular 
therapeutic area, the cost differential will be set by this process at 40%, and will 
not exceed that level. Preserving competition will depend on having more than 
one generic equivalent to every innovator, where possible in terms of patent 
law. 
5.2.2 Barriers to entry and drug importation 
In economics and especially in the theory of competition, barriers to entry are 
obstacles in the path of a firm which wants to enter a given market. In 
particular, in the pharmaceutical industry, barriers to entry include Government 
regulations, patents, customer loyalty, advertising and research and 
development. The patent system creates a monopoly-like power which results 
in very high prices. 
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A number of provisions exist that can weaken this stranglehold. The Medicines 
Act has already been amended to allow for parallel importation of medicines, 
based on the principle of international exhaustion of patent rights. Parallel 
importation would allow the importation of a drug, cheaper in another country, to 
be resold in South Africa, without authorization of the original seller. This would 
allow Government to search for the lowest world price. 
The Patents Act (Patents Act of South Africa, 1978) also makes provision for 
compulsory licensing. The Government could issue a license to a local 
company for a patented drug manufactured by a large pharmaceutical 
company. This local company would then manufacture the drug for sale in 
South Africa under a generic name and it would pay a reasonable royalty to the 
patent holder. 
Interestingly, neither of these provisions has been put into effect in South Africa. 
No parallel traded medicines have been marketed in the three years since 
section 15C of the 1997 amended Medicines and Related Substances Control 
Act 1965 (Medicines and Related Substances Act, 1965) became operable. 
This could be due to the bureaucratic barriers provided for in that section and 
the accompanying regulations, or it could be due to an inability to secure large 
enough volume suppliers of lower cost patented medicines in countries with 
acceptable medicines regulatory standards. Bolar provisions (whereby 
manufacturers of generic pharmaceuticals use the technology of a patented 
drug to perform work that would assist in the marketing or regulatory approval of 
the generic product, while the patent is in force) have been created in local 
patent law, and do, to some extent, aid generic entry. 
The greatest barriers to new generic entrants would, however, seem to be in the 
more traditional areas that are specific to the pharmaceutical industry. Long 
delays in obtaining marketing authorisation, high costs of imported technology 
and a lack of incentives from government would seem to be the dominant 
factors at play. Despite the NDP promise to "support the development of the 
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local pharmaceutical industry and the local production of essential drugs", little 
has been done in this area. 
5.2.3 Review of Algorithms 
As has been shown in this study, the current CMS CDL algorithms in some 
cases seem to be following a similar track to the public sector STG/EDLs, but in 
other cases vary considerably. In some cases, these additions or variations 
include expensive medicines for which few or no less expensive generic 
equivalents exist. The process whereby these algorithms have been developed 
is not transparent, nor are any reasons for additions or deletions provided. By 
contrast, the National Essential Drugs List (Department of Health, 1998A) 
committee is made up of Ministerial appointees. In terms of the National Health 
Act (Act 61 of 2003), (National Health Act, 2004) the Minister will be making 
regulations on "the development of an essential drugs list and medical and 
other assistive devices list" (section 90(1 )(d)). 
In order to improve the quality of the system, and also increase the degree of 
convergence between the public and private sectors, it is recommended that the 
National Essential Drugs List selection structures prescribed by these 
envisaged regulations also take on the task of determining the algorithms 
applicable to the ambulatory care PMBs, the CMS CDL. This is also in line with 
the intentions of the 1996 National Drug Policy. While the initial intention of the 
EDL was directed at public sector services ("The national list of essential drugs 
will be used as a foundation for: the basic health care package of the National 
Health System for Universal Primary Care; procurement and use of drugs; 
standard treatment guidelines and training in rational prescribing; drug 
information to health care providers, including a national formulary; support to 
the national pharmaceutical industry; drug donations"), the policy went on to 
state: "The list may also be used as a model for medical aid schemes" . 
(Department of Health, 1996) 
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In particular, a more direct and prescriptive approach could reduce costs - for 
example, where the algorithm specifies a therapeutic class of drugs. In the 
algorithm for cardiac failure, ACE inhibitors are a recommended line of 
treatment. There are 11 'Me-Too' originator drugs within the class of ACE 
inhibitors, with a total number of 31 generic equivalents. The cost differentials 
between the originator drugs themselves is 77% (between captopril and 
lisinopril) while the lowest cost differential between originator and their generic 
equivalent is 35% (fosinopril). The onus of cost saving is transferred to medical 
schemes, which may specify in their formularies which medicines in the class 
they will cover fully. This problem can be addressed either by more specific 
algorithms, or by the use of therapeutic reference pricing. It would, however, 
demand a far more rigorous approach to documenting the decision-making 
process and a commitment to an evidence-based approach. Even in countries 
where this has been attempted, there have been attacks on the structures 
responsible. In the United Kingdom, the National Institute for Health and Clinical 
Excellence has been criticized, and in Germany, the equivalent structure, the 
Institute for Quality and Economic Efficiency in Health Care has been accused 
of a lack of transparency (Tufts, 2006). 
5.3 Specific recommendations 
The CMS CDL algorithms should follow the public sector STG/EDLs more 
closely. This can be achieved by utilising the National Essential Drugs List 
selection structures to determine the algorithms for use as by medical schemes. 
The algorithms need to be more specific especially in the area where there are 
many drugs available in one therapeutic group. 
In relation to the pricing section of the National Drug Policy, Government needs 
to define more clearly how they are going to control prices. Regulating prices 
by stipulating what dispensing fees may be charged does not take into 
consideration all the other costs along the distribution chain. Government's 
intervention in relation to the single exit price can be seen as a step towards 
rectifying this problem. However, in Figure 4.4 the proposed figure of generics 
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being 40% lower than the SEP of the originator drug has been shown, in this 
study, to be too low. As stated previously (section 4.3.4) 67.5% of all generics 
for chronic diseases have cost differentials greater than 40%. Government 
needs to reassess this figure. Greater competition must also be encouraged by 
reducing barriers to entry. 
The provisions that exist to weaken barriers to entry must be taken up by the 
Government. More effort must be made to implement parallel imports as this 
can be an important source of price competition for medicines and would be a 
tool to lower prices for consumers. 
Compulsory licensing would not only lower prices to consumers by creating 
competition in the market for the patented good but would boost the economy 
by encouraging investment into the manufacturing of these medicines. 
However, Government would also need to look at offering incentives to these 
companies by means of reduced tariffs on imported technology and changing 
legislation which will reduce the amount of time it takes to obtain marketing 
authorization. 
The impact on prices would be similar to the introduction of generic competition 
at the end of a drug's patent term i.e. prices would decrease significantly. 
The majority of drug information or advertising is usually released by the actual 
manufacturing companies. As Government and universities can play an 
important role in educating undergraduate and postgraduate doctors on generic 
substitution, a change in the quality of drug information available to students 
should be considered. Consumers should be made more aware of their rights 
with regard to generic substitution and prescribing. 
The mechanisms to implement the majority of these recommendations are 
already in place within South Africa. However, only when Government is able 
to realise the aims specified in the National Drug Policy (1996) will consumers 
benefit from lower drug prices. 
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5.3 Conclusion 
This study has shown that there is potential for cost savings by comparing the 
single exit price of originator drugs and their generic equivalents. This has been 
done within a South African context concentrating on the chronic disease list. 
All of the objectives as stated in chapter one have been covered and the data 
collected and analyses conducted in chapter four have allowed these objectives 
to be achieved. Subsequently, the information taken from the various analyses 
has provided the basis for the recommendations. 
It is recommended that further research be undertaken, especially in the area of 
addressing price controls as a more realistic benchmark percentage to be set 
by Government needs to be investigated. 
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Diagnosis L _ —I Disease identification card or disc recommended 
I 
Oral corticosteroid replacement in divided doses 
Adjust lo individual needs 
i ~ 
Defective aldosterone secretion and/or 
still insufficient mineral corticoid effect 
4 , 
Add fludrocortisone 50- iOO^g daily-
Adjust to patient's needs 
t 
Monitor BP, weight, as well as 
electrolytes during therapy 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
In stressed ill patients 




Made on symptoms and signs 
Objective measurement: 
FEVl improvement possible > 15% 
[& 200ml increase after short actingj&2 agonist (4Q0|Jg MD! and spacer)] 
V 
Aims of Management; 
Control symptoms and prevent exacerbations 
Achieve best possible peak flow 
Minimise adverse effects 
Stepwise Approach: 
Start treatment at step most apporopriate to initial severity 
Achieve early control 
Maintain stepping up or stepping down therapy 
CLASSIFICATION OF SEVERITY 
Management of Chronic Asthma in Adults 
Classify Severity at Presentation 
Intermittent Persistent 
Mild Moderate Severe 
















START TREATMENT AT MOST APPROPRIATE STEP 
t 
I 
Step 1: Mild Intermittent Asthma 
Inhaled short acting fi2 agonist as required 
Step 2: Mild Persistent Asthma 
Reliever: fi2 agonist as required; 
Preventer: Add inhaled corticosteroid 400-800\xg/&dy 
(Equivalent to beclomethasone MDI & spacer) l 
ASTMA 
± 
Step 3: Moderate Persistent Asthma 
1. Short-acting J32 agonist as required 
2. Increase dose of inhaled cortisostemid to 1200 fig/day 
(beclomethasone or equivalent) 
if not controlled 
3. Add inhaled long-acting fi2 agonist (LAfiA) to 
1200 jag/day inhaled corticosteroid (beclomethasone or 
equivalent) 
4. Reassess control: 
• If adequate: continue LAfiA 
• If no response: stop LAfiA; consider SR 
theophylline 
Step 4: Severe Persistent Asthma 
1. Short-acting fi2 agonist as required 
2. Increase inhaled steroid to 2000 pg/day 
(beclomethasone or equivalent): plus LAfiA 
or SR theophylline 
Step 5: Very Severe Persistent Asthma 
1. Therapy as in Step 4 
2. Review for oral steroids 
• /?2 - Beta-2 receptor 
• MDI - Metered dosage inhaler 
• PEF - Peak expiratory flow 
• LAP A - Long acting beta-2 receptor agonist 
• SR - Slow release 
Applicable ICD 10 Coding: 
• J45 Asthma 
o J45.0 Predominantly allergic 
o J45.1 Nonallergic asthma 
o J45.8 Mixed asthma 
o J45.9 Asthma, unspecified 
• J46 Status asthmaticus 
asthma 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 




Treat underlying cause if possible e.g. COPD 
" 
Life style modifications 
No smoking and avoid other irritants 
Postural drainage 
I 
Treat airways obstruction and complications 





Stable with mild bronchiectasis: 
E.g. 
Amoxycillin 500 mg 8 hourly for 14 days 
Or 
Doxycycline 100 mg twice daily for 14 days 
May need prolonged therapy in some cases up to 3 weeks 
* 
Further antibiotic therapy should be based on sputum 
microscopy, culture and sensitivity investigations 
Glossary: 
• COPD - Chronic obstructive pulmonary 
Applicable ICD 10 Coding: 
• J47 Bronchiectasis 
• Q33.4 Congenital bronchiectasis 
disease 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
CARDIAC FAILURE 
Diagnosis AH patients should have once only pneumococcal 
immunisation and annual influenza immunisation 
Patients should avoid salt rich food; 
Exercise as per individualised 
programme; 
Consume only 1-2 units of alcohol per 
day (except if alcohol induced); 
Stop smoking and lose weight. 
I 
Consider ACE inhibitor in 
all patients 
A.ddfi-blocker in patients with 
ongoing symptoms who have 
NYHA class 11 - III symptoms 
I 
Add diuretic if patient is fluid overloaded 
Use thiazide if normal renal function 
or 
Loop diuretic if impaired renal function and volume overloaded 
Monitor serum K+, consider replacement therapy if necessary 
Continued symptoms? 
I 
Consider loop diuretic if impaired 
renal function and volume 
overloaded and NYHA class 111/IV 
Add spironolactone low dose if 
NYHA class III/IV 
Monitor serum K+ 
I 
Consider digoxin in patients with NYHA class 
1II/1V with persisting symptoms, very poor LV 
function or persisting cardiomegaly 
I 
Stan with low dose digoxin in 
elderly 0.125 mg/day 
If systolic failure refractory to treatment, 
review 
NOTE: If patient truly intolerant to ACE inhibitor, consider hydralazine & isosorbide dinitrate combination 
therapy 
Glossary: 
• ACE inhibitor - Angiotensin converting enzyme inhibitor 
• Serum K+ - Serum potassium 
• fi-b!ocker - Beta-receptor blocker 
• NYHA - New York Heart Association 
• LV - Left ventricular 
Applicable ICD 10 Coding: 
• 150 Heartfailure 
o 150.0 Congestive heart failure 
o 150.1 Left ventricular failure 
o 150.9 Heart failure, unspecified 
• II 1.0 Hypertensive heart disease with (congestive) heart failure 
• 113.0 Hypertensive heart and renal disease with (congestive) heart failure 
• 113.2 Hypertensive heart and renal disease with both (congestive) heart failure and 
renal failure 
Note: 
Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
*-rti\-L/lV*i*i » yjt rvi 
Diagnosis All patients should have once only 
pneumococcal immunisation and 
annual influenza immunisation 
Patients should avoid salt rich foods; 
Exercise as per individualised programme; 
Consume only 1-2 units of alcohol per day {except if 
alcohol induced); 
Stop smoking and lose weight; 
Adequate contraception is essential in patients wiih 
previous peripartum cardiomyopathy. 
Add warfarin if atrial 
fibrillation or history 
of an embolic event 
Consider ACE 
inhibitor in all 
patients 
Add fi-blocker in paiients with ongoing 
symptoms who have NYHA class II - III 
symptoms and are euvolaemic 
Add diuretic if patient is fluid 
overloaded 
Use thiazide if normal renal function 
or 
Loop diuretic if impaired renal 
function and volume overloaded 
Continued 
symptoms? 
Consider loop diuretic if impaired renal function and 
volume overloaded and NYHA class Ill/TV 
Monitor serum K+, consider replacement if necessary 
Add spironolactone low dose if 
NYHA class Iimv 
Monitor serum K+ 
Consider digoxin in patients with NYHA class II1/IV 
with persisting symptoms, atrial fibrillation, very poor 
LV function or persisting cardiomegaly 
Start with low dose digoxin in 
elderly 0,125 mg/day 
If systolic failure refractory to treament, 
review 
NOTE: If patient truly intolerant to ACE inhibitor, consider hydralazine & isosorbide dinitraie combination 
therapy 
Glossary: 
• ACE inhibitor - Angiotensin converting enzyme inhibitor 
• Serum K+ - Serum potassium 
• fi-blocker - Beta-receptor blocker 
• NYHA - New York Heart Association 
• LV - Left ventricular 
Applicable ICD 10 Coding: 
• 142 Cardiomyopathy 
o 142.0 Dilated cardiomyopathy 
o 142.1 Obstructive hypertrophic cardiomyopathy 
o 142.2 Other hypertrophic cardiomyopathy 
o 142.3 Endomyocardial (eosinophilic) disease 
o 142.4 Endocardial fibroelastosis 
o 142.5 Other restrictive cardiomyopathy 
o 142.6 Alcoholic cardiomyopathy 
o 142.7 Cardiomyopathy due to drugs and other external agents 
o 142.8 Other cardiomyopathies 
o 142.9 Cardiomyopathy, unspecified 
• 125.5 Ischaemic cardiomyopathy 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
CHRONIC RENAL DISEASE 
Diagnosis 
Mild Chronic Renal failure 
Cr 100-200 umol/1 
Moderate Chronic Renal failure 
Cr 200-400 umol/1 
Severe Chronic Renal failure 
Cr > 400 umol/1 
Mild Chronic Renal Failure (Cr 100-200 umol/I) 
Treat hyprtension vigorously i.e. BP < 130/85 mmHg 
Avoid diuretics unless volume overloaded 
Usually 3 agents required especially when Cr > 150 fimol/1 
Target BP < 130/85 mmHg 
Use ACE inhibitors: retard decline and are anti-proteinuric; more effective if Na+ depleted 
or Calcium antagonist: have proven reno-protective effects, but not anti-proteinuric 
Add thiazide diuretic to augment ACE inhibitor or add 
fi-blocker as combination therapy 
Continue monitoring renal function and hlood pressure 
Moderate Chronic Renal Failure (Cr 200-400 M_mol/l) 
Treat hypertension vigorously i.e. BP< 130/85 mmHg 
Avoid diuretics unless volume overloaded 
Usually 3 agents required, target BP < 130/S4 mmHg 
Use ACE inhibitors: retard decline and are anti-proteinuric; more effective if Na+ depleted 
or Calcium antagonist: have proven reno-protective effects, but not anti-proteinuric 
i f 
Add thiazide diuretic to augment ACE inhibitor or 
add fi-blocker as combination therapy 
1 r 
Continue monitoring renal function and biood pressure 
Prevent Osteodystrophy 
Give phosphate binder with meals 
[Calcium carbonate) 
Reserve la-hydmxy cholecalciferol for 
hypocalcemia or progressive hyperparathyroidism 
Monitor serum Ca++ and/or P(T for hiyh levels 
Prevent Anaemia 
Treat iron deficiency 2-3 mg/kg/day 
elemental iron orally 
Treat with IV iron therapy if necessary 
Treat folate deficiency 
2,5-5 mg/day folic acid 
Iron therapy failure: 
Erythropoietin when Hb < 8 gm/df 
Severe Chronic Renal Failure (Cr > 400 nmol/1) 
Patients require early nephrological referral for 
management and assessment for dialysis and transplant 
Glossary: 
• ACE inhibitor - Angiotensin converting enzyme inhibitor 
• Serum Na+ - Serum sodium 
• P-blocker - Beta-receptor blocker 
• BP - Blood pressure 
• Hb - Haemoglobin 
• Cr/Serum Cr - Serum creatinine 
• Serum Ca++ - Serum calcium 
• la-hydroxy- 1-alpha-hydroxy 




Applicable ICD 10 Coding: 
• N03 Chronic nephritic syndrome 
o N03.0 Chronic nephritic syndrome, 
N03.1 Chronic nephritic syndrome, 
N03.2 Chronic nephritic syndrome, 
N03.3 Chronic nephritic syndrome, 
glomerulonephritis 
N03.4 Chronic nephritic syndrome, 
glomerulonephritis 
N03.5 Chronic nephritic syndrome, 
glomerulonephritis 
N03.6 Chronic nephritic syndrome, 
N03.7 Chronic nephritic syndrome, 
N03.8 Chronic nephritic syndrome, 
N03.9 Chronic nephritic syndrome, 
o 
o 
minor glomerular abnormality 
focal and segmental glomerular lesions 
diffuse membranous glomerulonephritis 
diffuse mesangial proliferative 
diffuse endocapillary proliferative 
diffuse mesangiocapillary 
dense deposit disease 
diffuse crescentic glomerulonephritis 
other 
unspecified 
• Nil Chronic tubulo-interstitial nephritis 
o Nl 1.0 Nonobstructive reflux-associated chronic pyelonephritis 
o Nl 1.1 Chronic obstructive pyelonephritis 
o Nl 1.8 Other chronic tubulo-interstitial nephritis 
o Nl 1.9 Chronic tubulo-interstitial nephritis, unspecified 
• N18 Chronic renal failure 
o N18.0 End-stage renal disease 
o N18.8 Other chronic renal failure 
o N18.9 Chronic renal failure, unspecified 
• 112.0 Hypertensive renal disease with renal failure 
• 113.2 Hypertensive heart and renal disease with both (congestive) heart failure and 
renal failure 
• O10.2 Pre-existing hypertensive renal disease complicating pregnancy, childbirth 
and the puerperium 
• O10.3 Pre-existing hypertensive heart and renal disease complicating pregnancy, 
childbirth and the puerperium 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE 
Diagnosis 
All patients should stop smoking, avoid irritants and 
have an annual influenza immunisation 
Early effective treatment of exacerbations 
Stage 1 
FEV1 at least 50% of predicted 
Mild effort-related dyspnoea 
Stage II 
FEV1 35-49% of predicted 
Continuous dyspnoea 
Bronchodilators. relieve symptoms, do not alter 
decline in KEV1 
fi2 agonist inhaler: 2 puffs 6 hourly as needed or 
Ipratropium bromide inhaler: 2 puffs 6 hourly as 
needed or 
Combination of above: 6 hourly as needed 
and 
Oral theophylline 6-8 mg/kg/day in divided doses 
adjusted to plasma trough levels 
Stage III 




Consider oral corticosteroid trial: 
prednisone. 40 mg/day for 14 days 
Bronchodtiators: relieve symptoms, do not 
alter decline in FEV1 
fi2 agonist inhaler: 2 puffs 6 hourly as needed 
or 
Ipratropium bromide inhaler: 2 puffs 6 hourly 
as needed or 
Combination of above: 6 hourly as needed 
and 
Oral theophylline 6-8 mg/kg/day in divided 
doses adjusted to plasma trough levels 
& 
Oral corticosteroid trial: prednisone 
40 mg/day for 14 days 
Improvement of FEV1 < 10% and 
significant symptomatic improvement 
Objective improvement in 
FEV1 of>12%and>200m! 
to more than 80% 
predicted 
Treat as for Asthma 
Consider the risk-benefit of low dose 
prednisone 10 mg alternate days or 5 mg 
daily and optimise 
bronchodilator dierapy 
Severe advanced disease 
No objective response: 
Stop corticosteroids 
Optimise bronchodilator 
therapy and other 
supportive therapy 
Consider long term domiciliary oxygen 
Treat complications 
Prevent weight loss 
Glossary: 
• FEV1 - Forced expiratory volume in 1 second 
• fi-blocker - Beta-2 receptor 
Applicable ICD 10 Coding: 
• J43 Emphysema 
o J43.0 MacLeod's syndrome 
o J43.1 Panlobular emphysema 
o J43.2 Centrilobular emphysema 
o J43 8 Other emphysema 
o J43.9 Emphysema, unspecified 
• J44 Other chronic obstructive pulmonary disease 
o J44.0 Chronic obstructive pulmonary disease with acute lower respiratory 
infection 
o J44.1 Chronic obstructive pulmonary disease with acute exacerbation, 
unspecified 
o J44.8 Other specified chronic obstructive pulmonary disease 
o J44.9 Chronic obstructive pulmonary disease, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
CORONARY ARTERY DISEASE 
Diagnosis 
Address and manage risk factors: 
Lifestyle modification: 
Stop smoking, modify diet, increase aerobic exercise and limit alcohol 
consumption to 2 units/day 
HyperMpidaemia 1 
Diabetes mellitus > Manage as per disease-specific algorithm 
Hypertension J 
All patients should receive aspirin 75-325 mg/day 
(unless contra indicated) 
Sublingual nitrates for short term 
control of angina symptoms 









If symptoms uncontrolled: 
Add long acting nitrate or a 





Treat with rate limiting 
calcium channel antagonist; 
a long acting dihydropyridine or a 
'long" acting nitrate 
If symptoms uncontrolled add one of 
the other alternatives 
Review if: 
uncontrolled symptoms; 
symptoms limit patient's desired activities; patients at high risk 
Glossary: 
• [i-receptor antagonist - Beta-receptor antagonist 
Applicable ICD 10 Coding: 
• 120 Angina pectoris 
o 120.0 Unstable angina 
o 120.1 Angina pectoris with documented spasm 
o 120.8 Other forms of angina pectoris 
o 120.9 Angina pectoris, unspecified 
• 125 Chronic ischaemic heart disease 
o 125.0 Atherosclerotic cardiovascular disease, so described 
o 125.1 Atherosclerotic heart disease 
o 125.2 Old myocardial infarction 
o 125.3 Aneurysm of heart 
o 125.4 Coronary artery aneurysm 
o 125.5 Ischaemic cardiomyopathy 
o 125.6 Silent myocardial ischaemia 
o 125.8 Other forms of chronic ischaemic heart disease 
o 125.9 Chronic ischaemic heart disease, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
Glossary: 
• 5-ASA - 5-Aminosalicylic acid 
• IV - Intravenous 
Applicable ICD 10 Coding: 
• K50 Crohn's disease [regional enteritis] 
o K50.0 Crohn's disease of small intestine 
o K50.1 Crohn's disease of large intestine 
o K50.8 Other Crohn's disease 
o K50.9 Crohn's disease, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
DIABETES INSIPIDUS 
Diagnosis of central diabetes 
insipidus usually via water 
deprivation test 
1 
Rule out and treat any 
underlying cause 
J 
Treat if symptoms are 
debilitating 
I 
Treat with desmopressin 
Dosage form appropriate for patient 
Oral or nasal spray/solution 4 times dai 
depending on response! 
J_ 
Use lowest dose possible to control symptoms 
Avoid unplanned treatment withdrawal 
Patient education essential regarding adherence 
Applicable ICD 10 Coding: 
• E23.2 Diabetes insipidus 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
Disease identification card 




b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
DIABETES MELLITUS TYPE 1 
Diagnosis of Type 1 
Lifestyle modification 
Home glucose monitoring essential 
j Disease identification card ' 
. or disc recommended I 
Monitor HbA Ic at 3-6 monthly intervals 
Insulin for all 
Individualsauon essential 






If conventional regimen, an intensive insulin 
regimen may be indicated 
Review by specialist physician if necessary 
Glossary: 
• HbAlc - Glycosylated haemoglobin 
Applicable ICD 10 Coding: 
• E10 Insulin-dependent diabetes mellitus 
o El0.0 Insulin-dependent diabetes mellitus with coma 
o El0.1 Insulin-dependent diabetes mellitus with ketoacidosis 
o El0.2 Insulin-dependent diabetes mellitus with renal complications 
o El0.3 Insulin-dependent diabetes mellitus with ophthalmic complications 
o El0.4 Insulin-dependent diabetes mellitus with neurological complications 
o El0.5 Insulin-dependent diabetes mellitus with peripheral circulatory 
complications 
o El0.6 Insulin-dependent diabetes mellitus with other specified complications 
o E10.7 Insulin-dependent diabetes mellitus with multiple complications 
o El0.8 Insulin-dependent diabetes mellitus with unspecified complications 
o El0.9 Insulin-dependent diabetes mellitus without complications 
• El2 Malnutrition-related diabetes mellitus 
o El2.0 Malnutrition-related diabetes mellitus with coma 
o El2.1 Malnutrition-related diabetes mellitus with ketoacidosis 
o El2.2 Malnutrition-related diabetes mellitus with renal complications 
o El2.3 Malnutrition-related diabetes mellitus with ophthalmic complications 
o El2.4 Malnutrition-related diabetes mellitus with neurological complications 
o El2.5 Malnutrition-related diabetes mellitus with peripheral circulatory 
complications 
o El2.6 Malnutrition-related diabetes mellitus with other specified 
complications 
o El2.7 Malnutrition-related diabetes mellitus with multiple complications 
o El2.8 Malnutrition-related diabetes mellitus with unspecified complications 
o El2.9 Malnutrition-related diabetes mellitus without complications 







diabetes mellitus, insulin-dependent 
malnutrition-related diabetes mellitus 
diabetes mellitus, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
DIABETES MELLITUS TYPE 2 
Diagnosis of Type 2 
Address other risk factors 
Lifestyle modification as pan of inilia! management 
Measure HbAlc every 3 months depending on 
control and changes in therapy 
Disease 
identification card or 
disc recommended 
Target HbAlc should be < 7.0% 
JL 
Have lifestyle modifications been successful? 
NO 
Consider oral hypoglycaemic agents 





Continue to monitor 
HbAlc every 6 months 
NO 
Is Patient's BMI > 25? 
YES NO 
Use metformin Consider either metformin or a sulphonyiurea 
depending on plasma glucose 
Adequate control? 
NO YES 
Continue to monitor blood 
glucose and HbAlc 3-6 monthly 
i 
Optimise dose of oral hypoglycaemic agent 







If patient on sulphonyiurea and has normal 
renal function and has no cardiac dysfunction add 
metformin 
If poor renal function: 




blood glucose and 
HbAlc 3-6 
monthly 
Is control adequate? 
YES NO 
Monitor HbAlc 




• HbAlc - Glycosylated haemoglobin 
• BMI - Body mass index 
Applicable ICD 10 Coding: 
• El I Non-insulin-dependent diabetes mellitus 
o El 1.0 Non-insulin-dependent diabetes mellitus with coma 
o El 1.1 Non-insulin-dependent diabetes mellitus with ketoacidosis 
o El 1.2 Non-insulin-dependent diabetes mellitus with renal complications 
o El 1.3 Non-insulin-dependent diabetes mellitus with ophthalmic complications 
o El 1.4 Non-insulin-dependent diabetes mellitus with neurological 
complications 
o El 1.5 Non-insulin-dependent diabetes mellitus with peripheral circulatory 
complications 
o El 1.6 Non-insulin-dependent diabetes mellitus with other specified 
complications 
o El 1.7 Non-insulin-dependent diabetes mellitus with multiple complications 
o El 1.8 Non-insulin-dependent diabetes mellitus with unspecified complications 
o El 1.9 Non-insulin-dependent diabetes mellitus without complications 











El2.0 Malnutrition-related diabetes mellitus with coma 
E12.1 Malnutrition-related diabetes mellitus with ketoacidosis 
El2.2 Malnutrition-related diabetes mellitus with renal complications 
El2.3 Malnutrition-related diabetes mellitus with ophthalmic complications 
El 2.4 Malnutrition-related diabetes mellitus with neurological complications 
El2.5 Malnutrition-related diabetes mellitus with peripheral circulatory 
complications 
El2.6 Malnutrition-related diabetes mellitus with other specified 
complications 
El2.7 Malnutrition-related diabetes mellitus with multiple complications 
El2.8 Malnutrition-related diabetes mellitus with unspecified complications 
El2.9 Malnutrition-related diabetes mellitus without complications 




024.1 Pre-existing diabetes mellitus, non-insulin-dependent 
024.2 Pre-existing malnutrition-related diabetes mellitus 
024.3 Pre-existing diabetes metlitus, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
DYSRHYTHMIAS 
Chronic Atrial Fibrillation 
Diagnosis 
ZTZ 
A mi coagulate: 
warfarin (maintain INR: 2-3,5) 
If warfarin not tolerated, consider 
aspirin alone 
i 
Monitor heart rate 
Control: at rest < 80 beats/min 
exercise (6 min walk test) < I !0 beats/min 
i * 
Heart rate Bradycardia < 60 beats/min 
controlled: 
No treatment needed Review for permanent 
pacemaker 
Heart rate: > 80 beats/min at rest 
> 110 beats/min at exercise 
Treat with: 
1. fi-hlockers e.g. Atenolol 25-50 mg bd or, 
2. Digoxin 0,125-0,25 mg daily or, 
3. Verapamil, 
Or if treatment fails or not tolerated. 
4. Amiodarone 
" I ~ 
If treatment fails or not tolerated: 
Review for AV node ablation and 
permanent pacemaker 
Chronic Atrial Flutter 
Diagnosis 
Anticoagulate: 
warfarin (maintain INR: 2-3,5) 
If warfarin not tolerated, consider 
aspirin alone 
Review for cardioversion 












Assess ventricular rate: 
Clinically and/or Holter monitor 
Control: at rest < 80 beats/min 
exercise (6 min walk test) 
< 110 beats/min 
Heart rate inadequate? 
Consider trial of therapy: 
JS-blockers (7 days) or amiodarone (!4 days) 
If treatment fails or not tolerated 
z 




Review lor cardioversion 
Early recurrence post-conversion 
NO 
Exclude, assess and manage the following; 
• Acute myocardial infarct 
• Electrolyte imbalance 
• Left ventricular dysfunction 
Ventricular tachycardia persists 
fi-blockers e.g. atenolol 50mg bd if tolerated, 
or if LV function decreased or patient in heart 




Review tor electrophysiological studies 
Glossary: 
• INR - International normalized ratio 
• /^-blocker - Beta-receptor blocker 
• AV node - Atrioventricular node 
• LV - Left ventricular 
Applicable ICD 10 Coding: 
• 147.2 Ventricular tachycardia 
• 148 Atrial fibrillation and flutter 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 












Start with phenytoin or 
carbamazepine or 
sodium valpmate or valproic acid 
or phenobarbitone 
Not tolerated or controlled? 
Alternatives: 
Phenytoin or carbamazepine or 
sodium valproate or valproic acid or 
lamotrigine or topirwnate or 
oxcarbazepine 
Start with sodium 
valproate or valproic acid 
I 
Not tolerated or controlled? 
Alternatives and/or addition: 
For absent seizures: ethosuximide 
For myoclonic seizures: clonazepam 
For tonic-clonic seizures: carbamazepine or 
phenytoin or lamotrigine or topiramate or 
oxcarbazepine 
Ongoing seizures? Ongoing seizures? 
Add second drug 
Suggested combinations: 
Carbamazepine and sodium valpmate or 
valproic acid, 
Phenytoin and sodium valproate or valproic 
acid, 
Sodium valproate or valproic acid and 
lamotrigine, 
Anticonvulsant and topiramate 
Add second drug: 
If taking sodium valproate or valpmic acid for 
absent seizures add ethosuximide 
If taking sodium valproate or valpmic acid for 
myoclonic seizures add clonazepam 
If taking sodium valproate or valproic acid for 
tonic-clonic seizures add lamotrigine 
Uncontrolled seizures 
Review for further management 
Uncontrolled seizures 
Review for further management 
Applicable ICD 10 Coding: 











G40.0 Localization-related (focal)(partial) idiopathic epilepsy and epileptic 
syndromes with seizures of localized onset 
G40.1 Localization-related (focal)(partial) symptomatic epilepsy and epileptic 
syndromes with simple partial seizures 
G40.2 Localization-related (focal)(partial) symptomatic epilepsy and epileptic 
syndromes with complex partial seizures 
G40.3 Generalized idiopathic epilepsy and epileptic syndromes 
G40.4 Other generalized epilepsy and epileptic syndromes 
G40.5 Special epileptic syndromes 
G40.6 Grand mal seizures, unspecified (with or without petit mal) 
G40.7 Petit mal, unspecified, without grand mal seizures 
G40.8 Other epilepsy 
G40.9 Epilepsy, unspecified 






G41.0 Grand mal status epilepticus 
G41.1 Petit mal status epilepticus 
G41.2 Complex partial status epilepticus 
G41.8 Other status epilepticus 
G41.9 Status epilepticus, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 






Review for surgery 
1 
Open angle 
Start with Ji-blocker 
eye drops 
Con traindicat ion s ? 
Alternative first-line topical monotherapies: 
a2-agonist, 
carbonic anhydrase inhibitor, 
prostaglandin analogue 
Intolerance? 
Decrease dose or 
switch to alternative 
first line agent 
Poor response? 
Check adherence 
Increase dose if possible 
Switch to alternative first line agent 
Inadequate response to monotherapy? 
Check adherence 
Try combination iherapy, using the first line agents 
Intolerance? 
Decrease dose or switch 
to alternative 
combination 
Inadequate response to 
combination first line agents' 
Check adherence 
I 
Review for further medication or surgery 
Glossary: 
• /3-blocker Beta-receptor blocker 
a2-agonist - Alpha-2 receptor agonist 
Applicable ICD 10 Coding: 










H40.0 Glaucoma suspect 
H40.1 Primary open-angle glaucoma 
H40.2 Primary angle-closure glaucoma 
H40.3 Glaucoma secondary to eye trauma 
H40.4 Glaucoma secondary to eye inflammation 
H40.5 Glaucoma secondary to other eye disorders 
H40.6 Glaucoma secondary to drugs 
H40.8 Other glaucoma 
H40.9 Glaucoma, unspecified 
• Q 15.0 Congenital glaucoma 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 





Factor VHI 5-40% of 
the normal value 
Disease identification card 
or disc recommended 
Moderate Disease 
Factor VIII 1-5% of the 
normal value 
Desmopressin response study 
Effective Ineffective 
Severe Disease 
Factor VIII < I % of the 
normal value 
All require bleeding charts 
Home-based action plan 
Factor VJU available for self initiated therapy 
Desmopressin 
prophylaxis before 




surgery and dental 
procedures 
I 





paracetamol and opiods 
Not NSAIDs or aspirin 
Non-drug measures e.g. 
ice packs; bed rest; no 
weight bearing if possible; 













Fill in bleeding chart 








Disease identification card 
or disc recommended 
Moderate Disease 
Factor IX 1-5% of the 
normal value 
Severe Disease 
Factor IX < 1% of the 
normal value 
Will require Factor IX prophylaxis 
before surgery and denial 
procedures 
All require bleeding charts 
Home-based action plan 
Factor IX available for self initiated therapy 




paracetamol and opiods 
Not NSAID's or aspirin 
Non-drug measures e.g. ice 
packs; bed rest; no weight 
bearing if possible; 











Fill in bleeding chart 




• Factor VIII - Factor eight 
• Factor IX - Factor nine 
• NSAIDs Non-steroidal anti 
Applicable ICD 10 Coding: 
• D66 Hereditary factor VIII 
•inflammatory agents 
deficiency 
• D67 Hereditary factor IX deficiency 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
HYPERLIPIDAEMIA 
Fasting plasma 
TC > 5mmol/l 
YES NO 
Manifest coronary heart disease? 
Other risk factors? 




Full risk assessment, Fasting TG, TC, HDLC, LDLC 





Follow-up in 5 years 
Primary hyperlipidaemia Secondary hyperlipidaemia 
Does the patient have: 
Genetic dyslipidaemia 
with LDLC > 3mmol/l? or 
Established vascular 
disease? 
Treat cause of secondary hyperlipidaemia 
Lifestyle modification 







10 year Ml risk > 207c 
60 years age risk > 30% 
Utilise Framingham Risk Score 
YES NO 
Consider drug therapy 
Life stvle & risk-factor modification 
Lifestyle modification 





Consider the use of a statin 
Use the lowest dose possible 
to achieve target response 
Predominant 
hypcrtriglycendacmia 

















• TC - Total cholesterol 
• TG - Triglycerides 
• HDLC - High density lipoproteins cholesterol 
• LDLC - Low density lipoproteins cholesterol 
• Ml - Myocardial infarct 
Applicable ICD 10 Coding: 
• E78.0Pure hypercholesterolemia 
• E78.1 Pure hyperglyceridaemia 
• E78.2 Mixed hyperlipidaemia 
• E78.3 Hyperchylomicronaemia 
• E78.4 Other hyperlipidaemia 
• E78.5 Hyperlipidaemia, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
HYPERTENSION 
Measure BP in 
silting position 
i 
Systolic <130mmHg and 











1 f ' 




Recheck within 2 months 
1 
Systolic >140mmHg of 
or diastolic >90mmHg 
U 










Revie w tn 6 months 
Initial drug choices 
(unless conlraindicaied) 
For uncomplicated hypertension 
Start with diuretic 
Compelling Indications 
Angina: fi-blocker, CCB 
Prior myocardial infarct or CAD: fi-blocker and ACE inhibitor 
Post Ml: fi-blocker ot ACE inhibitor (in patients with systolic dysfunction) 
Heart Failure: ACE inhibitor, fi-blocker, diuretics (furosemide or 
spironolactone) 
Left ventricular hypertrophy: ACE inhibitor 
Stroke: Low dose diuretic: ACE inhibitor 
Type 1 Diabetes with proteinuria: ACE inhibitor, usually in combination with 
diuretic 
Type 2 Diabetes with microalbuminuria: ACE inhibitor or ARB, usually in 
combination with diuretic 
Type 2 Diabetes without proteinuria: ACE inhibitor, usually in combination with a 
diuretic 
Type 2 Diabetes with proteinuria: ACE inihibiior or ARB usually in combination 
with diuretic 
Isolated systolic hypertension (elderly): diuretic preferred (low dose thiazides), 
long-acting CCB 
Prostatism: a-blocker {this should not be used as monotherapy) 
Start with low dose 
and titrate if necessary 
Goal BP not achieved: 
<140/90 mmHg in uncomplicated cases, 








drug from different 
class 
Add second agent from 
different class (especially diuretic 
if not already used) 
Goal BP not achieved 
Add agent from different class or review 
Glossary: 
• a-blocker - Alpha-receptor blocker 
• ACE inhibitor - Angiotensin converting enzyme inhibitor 
• ARB - Angiotensin receptor blocker 
• BP - Blood pressure 
• fi-blocker - Beta-receptor blocker 
• CCB - Calcium channel blocker 
• CCF - Chronic / Congestive cardiac failure 
• CAD - Coronary artery disease 
• LV - Left ventricular 
• Ml -Myocardial infarct 
Applicable ICD 10 Coding: 
• 110 Essential (primary) hypertension 
• II1 Hypertensive heart disease 
o 111.0 Hypertensive heart disease with (congestive) heart failure 
o II1.9 Hypertensive heart disease without (congestive) heart failure 
• 112 Hypertensive renal disease 
o 112.0 Hypertensive renal disease with renal failure 
o 112.9 Hypertensive renal disease without renal failure 
•113 Hypertensive heart and renal disease 
o 113.0 Hypertensive heart and renal disease with (congestive) heart failure 
o 113.1 Hypertensive heart and renal disease with renal failure 
o 113.2 Hypertensive heart and renal disease with both (congestive) heart failure 
and renal failure 
o 113.9 Hypertensive heart and renal disease, unspecified 
• 115 Secondary hypertension 
o 115.0 Renovascular hypertension 
o 115.1 Hypertension secondary to other renal disorders 
o 115.2 Hypertension secondary to endocrine disorders 
o 115.8 Other secondary hypertension 
o 115.9 Secondary hypertension, unspecified 
• 010 Pre-existing hypertension complicating pregnancy, childbirth and the 
puerperium 
o O10.0 Pre-existing essential hypertension complicating pregnancy, childbirth 
and the puerperium 
o 010.1 Pre-existing hypertensive heart disease complicating pregnancy, 
childbirth and the puerperium 
o O10.2 Pre-existing hypertensive renal disease complicating pregnancy, 
childbirth and the puerperium 
o O10.3 Pre-existing hypertensive heart and renal disease complicating 
pregnancy, childbirth and the puerperium 
o 010.4 Pre-existing secondary hypertension complicating pregnancy, childbirth 
and the puerperium 
o O10.9 Unspecified pre-existing hypertension complicating pregnancy, 
childbirth and the puerperium 
• O l - l Pre-existing hypertensive disorder with superimposed proteinuria 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
HYPOTHYROIDISM 







No further testing DoFT4 
Normal 






Repeat FT4 and TSH 
I 
If TSH persistently 
elevated and patient 
symptomatic consider 
treating as for 
hypothyroidism 
I 
Start thyroxine 50u;g/day for 
2 weeks 
Then 100ug/day 
In elderly and patients with 
cardiac disease use low 
dose thyroxine 
Monitor TSH and FT4 every 





- Thyroid stimulating 
- Free thyroxine 
hormone 
Applicable ICD 10 Coding: 
• E01.8 Other iodine-deficiency-related thyroid disorders and allied conditions 
• E02 Subclinical iodine-deficiency hypothyroidism 
• E03 Other hypothyroidism 
E03.0 Congenital hypothyroidism with diffuse goitre 
E03.1 Congenital hypothyroidism without goitre 
E03.2 Hypothyroidism due to medicaments and other exogenous substances 
E03.3 Postinfectious hypothyroidism 
E03.4 Atrophy of thyroid (acquired) 
E03.5 Myxoedema coma 
E03.8 Other specified hypothyroidism 
E03.9 Hypothyroidism, unspecified 










1 Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
This algorithm was amended on 11 February 2005 






























Consider, oxybutinin or 
imipramine or amitnptyiine 
Pain 
Consider: amitnptyiine or 





• IV - Intravenous 
Applicable ICD 10 Coding: 










for 5 days 
(500mg to 1g daily) 
20 No. 27236 GOVERNMENT GAZETTE, 11 FEBRUARY 2005 
Note: 
1. Medical management reasonably necessary for the delivery of treatment 
described in this algorithm is included within this benefit, subject to the 
application of managed health care interventions by the relevant medical 
scheme. 
2. To the extent that a medical scheme applies managed health care 
interventions in respect of this benefit, for example clinical protocols for 
diagnostic procedures or medical management, such interventions must -
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into 
account considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical 
management is included within this benefit if It is supported by evidence-
based medicine, taking into account considerations of cost-effectiveness 
and affordability. 
ME TSHABALALA-MSIMANG 


























Levodopa with carbidopa in 





Levodopa with carbidopa 
in combination 
Consider addition of 
amantadine 
Advancing disease 
Add dopamine agonist 
Applicable ICD 10 Coding: 
• G20 Parkinson's disease 
• G21 Secondary parkinsonism 
o G21.0 Malignant neuroleptic syndrome 
o G21.1 Other drug-induced secondary parkinsonism 
o G21.2 Secondary parkinsonism due to other external agents 
o G21.3 Postencephalitic parkinsonism 
o G21.8 Other secondary parkinsonism 
o G21.9 Secondary parkinsonism, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 




Active erosive disease'.' 
NO YES 
T 
Non drug measures (rest, 
range-of-motion exercises) 
and add NSAID 
Non drug measures (rest, 
range-of-motion exercises) 








Add a DMARD 
e.g. methotrexate or sulphasalazine 
Corticosteroids may be necessary at all of 
these levels, to enable patient to be more 
functional while waiting for the DMARD 












• DMARD - Disease modifying antirheumatic drugs 
• NSAID - Non-steroidal anti-inflammatory agents 
Applicable ICD 10 Coding: 
• M05 Seropositive rheumatoid arthritis 
o M05.0 Felty's syndrome 
o M05.1 Rheumatoid lung disease (J99-0*) 
o M05.2 Rheumatoid vasculitis 
o M05.3 Rheumatoid arthritis with involvement of other organs and systems 
o M05.8 Other seropositive rheumatoid arthritis 
o M05.9 Seropositive rheumatoid arthritis, unspecified 
• M06 Other rheumatoid arthritis 
o M06.0 Seronegative rheumatoid arthritis 
o M06.1 Adult-onset Still's disease 
o M06.2 Rheumatoid bursitis 
o M06.3 Rheumatoid nodule 
o M06.4 Inflammatory polyarthropathy 
o M06.8 Other specified rheumatoid arthritis 
o M06.9 Rheumatoid arthritis, unspecified 
• M08.0 Juvenile rheumatoid arthritis 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 




Typical antipsychotic or atypical 
antipsychotic agent most appropriate and 
cost effective to suit patient's need 
V 
No response to one? 
Check adherence 
Use another typical antipsychotic or atypical antipsychotic 
Adherent but r 
response? 
Non-adherence? 
Use another typical 
antipsychotic or 
atypical antipsychotic 
Use depot formulation 
No response? 
No response? 
Use another depot formulation 
Clozapine 
No response? 
If partial response try adding 
augmentation agent e.g. mood 
stabiliser, antidepressant or ECT 
No response or refusal to 
use clozapine? 
Review for combination therapy of atypical antipsychotic 
as well as typical antipsychotic agents and ECT 
Glossary: 
• ECT - Electroconvulsive therapy 












F20.0 Paranoid schizophrenia 
F20.1 Hebephrenic schizophrenia 
F20.2 Catatonic schizophrenia 
F20.3 Undifferentiated schizophrenia 
F20.4 Post-schizophrenic depression 
F20.5 Residual schizophrenia 
F20.6 Simple schizophrenia 
F20.8 Other schizophrenia 
F20.9 Schizophrenia, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
SYSTEMIC LUPUS ERYTHEMATOSUS 
Diagnosis 
Education and appropriate 




Mild to moderate disease, 
non-organ threatening 




NSAIDs for symptomatic 
musculoskeletal manifestations 
Topical corticosteroids for skin disease 






High dose corticosteroids 
orally or pulse IV or cytotoxic 




Consider low dose aspirin 
Disease controlled and in remission? 
YES 
Consider the need for 
continued therapy 
NO 
Review for alternative 
therapy 
Glossary: 
• IV - Intravenous 
• NSAEDs - Non-steroidal anti-inflammatory agents 
• SLE - Systemic lupus erythematosus 
Applicable ICD 10 Coding: 
• M32 Systemic lupus erythematosus 
o M32.0 Drug-induced systemic lupus erythematosus 
o M32.1 Systemic lupus erythematosus with organ or system involvement 
o M32.8 Other forms of systemic lupus erythematosus 
o M32.9 Systemic lupus erythematosus, unspecified 
• L93 Lupus erythematosus 
o L93.0 Discoid lupus erythematosus 
o L93.1 Subacute cutaneous lupus erythematosus 
o L93.2 Other local lupus erythematosus 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
medical management, such interventions must— 
a. not be inconsistent with this algorithm; 
b. be developed on the basis of evidence-based medicine, taking into account 
considerations of cost-effectiveness and affordability; and 
c. comply with all other applicable regulations made in terms of the Medical 
Schemes Act, 131 of 1998. 
3. This algorithm may not necessarily always be clinically appropriate for the 
treatment of children. If this is the case, alternative paediatric clinical management 
is included within this benefit if it is supported by evidence-based medicine, taking 
into account considerations of cost-effectiveness and affordability. 
Glossary: 
• 5-ASA - 5-Aminosalicylic acid 
• IV - Intravenous 
Applicable ICD 10 Coding: 
• K51 Ulcerative colitis 
o K51.0 Ulcerative (chronic) enterocolitis 
o K51.1 Ulcerative (chronic) ileocolitis 
o K51.2 Ulcerative (chronic) proctitis 
o K51.3 Ulcerative (chronic) rectosigmoiditis 
o K51.4 Pseudopolyposis of colon 
o K51.5 Mucosal proctocolitis 
o K51.8 Other ulcerative colitis 
o K51.9 Ulcerative colitis, unspecified 
Note: 
1. Medical management reasonably necessary for the delivery of treatment described 
in this algorithm is included within this benefit, subject to the application of 
managed health care interventions by the relevant medical scheme. 
2. To the extent that a medical scheme applies managed health care interventions in 
respect of this benefit, for example clinical protocols for diagnostic procedures or 
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